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We should always have three friends in our lives: one who walks ahead, who we look up to 
and follow; one who walks beside us, who is with us every step of our journey; and then, one 






POPULAR SCIENCE SUMMARY OF THE THESIS 
Despite major advances in cancer treatment during the last century, cancer remains the leading 
cause of death. Together with surgery, radiotherapy and chemotherapeutics are cornerstones of 
cancer therapy and nearly all cancer patients receive some of these treatments. Radiotherapy 
(ionizing radiation) and chemotherapeutics kill cancer cells mostly by damaging the genetic 
material, the DNA. Cell death following DNA damage is a protective mechanism for the entire 
organism to prevent the generation of tumors as cancer can arise from mutations caused by 
DNA damage. Since normal cells are also vulnerable to DNA damage, these cancer therapies 
can damage healthy cells in the body. Thus, the treatment doses must be kept at a low enough 
concentration for the normal cells not to be harmed, which often leads to survival of some 
cancer cells. As a result, these therapies initially kill most of the cancer cells, leading to tumor 
shrinkage or disappearance, but some more resistant cancer cells may remain in the body and 
initiate new tumors, which results in relapse. Since the relapsed cancer has developed from the 
cancer cells that survived the treatment, the new tumor is often resistant to this treatment, and 
the patient can no longer be treated with the same therapy at safe doses.  
Cancer cells can become resistant to DNA damaging treatments by enhancing their DNA repair 
capacity. Therefore, targeted therapies are being developed which block the drivers of this 
enhanced DNA repair activity of cancer cells, and thus sensitize them to DNA damaging 
treatments while sparing normal cells. This thesis work focused on investigating the role of two 
proteins, CX3CR1 and PFKFB3, in DNA repair in cancer cells. The aim was to determine their 
molecular function and whether blocking of these cancer targets would impair DNA repair and 
sensitize them to DNA damaging chemo- (i.e. platinum drugs) and radiotherapy. Due to the 
lack of drugs blocking PFKFB3, we developed KAN0438757, a drug targeting PFKFB3. 
Along with KAN0438757, we evaluated if KAND567, a drug blocking CX3CR1, could be 
combined with platinum drugs and ionizing radiation to kill cancer cells.  
We reveal that PFKFB3 has a role in a certain type of DNA repair mechanism called 
homologous recombination repair and that inhibition of PFKFB3 by KAN0438757 blocks this 
repair and sensitizes cancer cells to ionizing radiation. Furthermore, we discovered that 
blocking CX3CR1 with KAND567 reduces survival of ovarian cancer cells, impairs their DNA 
replication, and has potential to sensitize cancer cells to ionizing radiation and platinum drugs. 
We continued this investigation by showing that CX3CR1 blockage leads to sensitization of 
especially platinum resistant cancer cells to platinum, without affecting normal cells. We 
discover that CX3CR1 regulates a specific DNA repair pathway, the Fanconi Anemia (FA) 
pathway, which repairs DNA damage caused by platinum drugs. Finally, we reveal that 
platinum resistant cancer cells are re-sensitized to platinum upon PFKFB3 inhibition. We 
further identify that PFKFB3 interacts with DNA repair proteins in the FA pathway and is key 
to establish a functional FA repair pathway. In summary, these studies reveal novel functions 
for CX3CR1 and PFKFB3 in DNA repair pathways in cancer cells and demonstrate that 
blocking their function by using targeted drugs results in cancer-specific sensitization to DNA 
damaging anti-cancer treatments, even in treatment-resistant cancer cells.  
ABSTRACT 
The goal of targeted cancer therapy is to selectively kill cancer cells based on their molecular 
survival mechanisms. DNA repair is as a promising cancer target as many cancers have chronic 
replication stress and deficiencies in the DNA damage response. Moreover, combining DNA 
damaging chemo- and radiotherapy with inhibitors of DNA repair can lead to improved 
treatment responses, reduced resistance to treatments, as well as lowering of effective doses 
and thereby reduced toxicity to healthy tissues. In this thesis, two cancer targets, CX3CR1 and 
PFKFB3, were investigated for their emerging roles in DNA repair. Furthermore, small 
molecule inhibitors KAN0438757, developed in Paper I to target PFKFB3, and KAND567 
targeting CX3CR1, were evaluated in combination treatments with ionizing radiation (IR) and 
platinum drugs in vitro.  
In Paper II and III we characterize the role of CX3CR1 in the DNA damage response. We 
reveal that CX3CR1 inhibition by KAND567 reduces cancer cell survival and impairs DNA 
replication, reducing RPA and ATR activation (Paper II). CX3CR1 inhibition increases DNA 
damage levels and S phase arrest when combined with platinum drugs, resulting in reduced 
cancer cell survival at doses not affecting non-transformed cells (Paper II and III). 
Mechanistically, we reveal that upon DNA damage induction CX3CR1 is relocated to the 
nucleus and regulates interstrand crosslink (ICL) repair by facilitating the recruitment of the 
key repair proteins in the Fanconi Anemia (FA) repair pathway, FANCD2 and FANCI, to the 
chromatin (Paper III). Notably, CX3CR1 inhibition sensitizes cancer cells to platinum 
treatment and especially platinum resistant cancer cell lines demonstrate good synergy for this 
combination treatment (Paper III). 
In Paper I and IV, we identify novel roles for PFKFB3 in regulating DNA repair. We show 
that PFKFB3 locates to DNA damage sites upon IR and PFKFB3 inhibition results in 
impairment of DNA double-strand break repair by homologous recombination (HR). 
Mechanistically, PFKFB3 triggers recruitment of RRM2, responsible of local nucleotide 
supply, and the HR factors, RPA and RAD51, to DNA damage sites, to allow for DNA repair 
(Paper I). Moreover, we develop a selective small molecule inhibitor, KAN0438757, that 
targets PFKFB3 and selectively radiosensitizes transformed cells (Paper I). In Paper IV, we 
discover a role for PFKFB3 in FA repair upon ICL induction in cancer cells. We demonstrate 
that PFKFB3 associates to the chromatin following treatment with ICL-inducing agents and 
regulates establishment of the FA repair pathway, needed for initiation of ICL repair. 
Importantly, we demonstrate that PFKFB3 inhibition synergizes with platinum treatments in 
blocking proliferation of transformed cells.  
In summary, our work identifies novel roles of CX3CR1 and PFKFB3 in DNA repair processes 
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The start of modern cancer research begun in the early 1900s and grew rapidly towards to the 
end of the century, resulting in expansion of treatment options and the discovery of cancer-
causing genes1. The 21st century marks the beginning of the era of targeted therapies with an 
increasing amount of cancer drugs brought into the clinic1. Cancer survival rates have 
dramatically increased over the decades due to advanced treatment options and screening 
programs allowing early detection of malignant lesions but, although some cancers are now 
curable, we still lack effective treatment options for many cancers. Today, personalized 
medicine approaches and analyses of whole cancer genomes by international research 
consortiums, along with improved methods to study cancer vulnerabilities, has led the way to 
a better understanding of this complex group of diseases with the aim to improve treatment 
responses and quality of lives2. 
1.1 THERAPEUTIC APPROACHES IN CANCER TREATMENT 
Cancer is often characterized by genome instability which is one of the enabling characteristics 
of cancer, as reviewed by Hanahan and Weinberg (2011)3. Along the progression of cancer, 
mutations occurring in the genome maintenance and surveillance systems endanger the 
integrity of the genome. This genome instability results in new mutations and genomic 
rearrangements driving cancer progression via selection of favorable phenotypes. However, 
genomic instable cancer cells are more vulnerable to DNA damage than non-malignant cells 
since their DNA repair machinery often is deficient4. This cancer cell vulnerability, along with 
the high proliferation rate of cancer cells, enables the usage of DNA damaging cancer 
treatments (Figure 1) such as ionizing radiation (IR) and chemotherapy, which have been used 
in cancer treatment for nearly a century4,5. However, genome instability in cancer is more 
elegantly harnessed by synthetic lethality approaches, described in Chapter 1.1.3, which target 
cancer cells specifically by directly interfering with drivers of cancer cell survival6. 
Chemotherapeutics are a diverse group of cytotoxic drugs with different, and usually with 
multiple, mechanisms of action7. This thesis work focused on studying the DNA crosslinkers 
platinum (cisplatin and carboplatin) and mitomycin C (MMC) chemotherapeutics as well as IR 
in synergistic treatments with small molecule inhibitors that target DNA repair. These cytotoxic 
agents distort the cells’ DNA in multiple ways, resulting in DNA damage which activates 
several DNA repair pathways (Table 1)8–12. The main aspects of DNA crosslinkers and IR in 
relation to DNA damage will be reviewed in this chapter, followed by introduction to the 
principles of synthetic lethality and drug synergy. Finally, ovarian cancer will be used as an 





Figure 1. Examples of 
DNA-damaging anti-
cancer treatments and the 
main types of DNA lesions 
they induce. In addition, all 
the chemotherapeutics 
interfere with DNA 
replication. This thesis 
focuses on radiotherapy 
and DNA crosslinkers 
(platinum drugs and 
Mitomycin C). The DNA 
damage caused by these 
agents is described in more 





Figure created based on the 
reviews by Helleday et al. 
(2008) and 
Jackson&Bartek (2009)5,13.  
 
 









Fanconi Anemia pathway (ICLs) 
Nucleotide excision repair 
Translesion synthesis  
Homologous recombination 
Non-homologous end-joining  
Mis-match repair 
Replicative bypass  
Ionizing radiation Double-strand breaks (40) 
Single-strand breaks (500-1000) 
Base damage (1000-2000) 
DNA crosslinks (30) 
DNA-protein (150) 
Sugar damage (800-1600) 
Homologous recombination (DSBs) 
Non-homologous end-joining (DSBs) 
alt-NHEJ 
Single-strand annealing 
Base excision repair  
Nucleotide excision repair 
Table 1. Various types of DNA damage caused by DNA crosslinkers (platinum and Mitomycin C) and ionizing 
radiation. The most relevant DNA damage responsible of cytotoxic effects and main repair pathways are 
highlighted in bold. Cursive displays different repair pathways involved in Fanconi Anemia repair of ICLs. The 
brackets show the amount of break/damage caused by one Gy of ionizing radiation and the % of ICLs caused by 
DNA crosslinkers of all crosslinks. Gy=Grey, ICL=interstrand crosslink, DSB=DNA double-strand break, 
SSB=DNA single-strand break, alt-NHEJ=alternative non-homologous end-joining, P=platinum, M=Mitomycin 
C. Table created based on references:8–12. 
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1.1.1 DNA crosslinkers  
Platinum drugs are some of the most commonly used anticancer drugs14. They react with the 
bases of DNA, resulting in DNA lesions and generation of DNA adducts which distort the 
structure of DNA, inhibiting replication and transcription, and activating multiple DNA repair 
mechanisms (Table 1)8,9,15. Intrastrand crosslinks comprise 90 % of the crosslinks and occur 
most frequently between adjacent purine residues on the same DNA strand16. In addition, 
platinum treatment results in the formation of DNA monoadducts, interstrand crosslinks (ICL) 
and DNA-protein crosslinks9. ICLs link two opposite DNA strands together, preventing their 
separation with irreversible covalent bonds. They constitute up to 5 % of the platinum damage 
but are the major cytotoxic lesion17,18. 
ICLs are considered the most severe type of lesion as they cause the replication machinery to 
stall while an intrastrand crosslinks can be bypassed by DNA polymerases15. ICLs are detected 
and removed via the Fanconi Anemia (FA) pathway in order to allow for replication to 
resume15,18. FA repair of ICLs involves coordination of multiple DNA repair pathways 
described in detail in Chapter 1.2.315. The cellular effects of platinum compounds are not 
limited to direct DNA damage—they also induce reactive oxygen species (ROS), including 
free radicals, which can cause damage to components of the cell by peroxidation of lipids and 
to the DNA through nucleic acid damage8. Moreover, platinum compounds can modulate 
apoptosis and survival signaling pathways and alter gene expression, some of which can 
contribute to development of platinum resistance in cancer cells8. 
Cisplatin (cis-diamminedichloroplatinum(II)) and its newer derivative carboplatin (cis-
diammine(1,1-cyclobutanecarboxylato)platinum(II)) generate intra- and interstrand crosslinks 
in similar ratio, but cisplatin is more reactive and has faster DNA binding kinetics than 
carboplatin8. In addition, carboplatin is retained longer in the body than cisplatin and has 
generally less side effects, which makes it more suitable for high-dose chemotherapy than 
cisplatin8,19. Carboplatin is preferred over cisplatin in the treatment of ovarian cancer, but due 
to lower efficacy in many other cancers, cisplatin is still widely used in anticancer treatment19.  
Mitomycin C (MMC) belongs to a group of cancer drugs called anti-cancer antibiotics due to 
the fact that it is naturally produced by the bacterium Streptomyces caespitosus. Following an 
enzymatic reduction of MMC, it is a potent crosslinker of DNA and causes ICLs by N-
alkylation of nucleosides20. It is estimated that the ICLs consists about 5-13 % of all lesions 
induced by MMC, which is about twice the amount of ICLs caused by platinum18. In addition 
to ICLs, MMC can also form DNA monoadducts21 and generate highly reactive free 
radicals20,22 (Table 1). MMC is used in the treatment of esophageal and bladder cancer but bone 
marrow toxicity (leukopenia and thrombocytopenia) limits its use7,15. 
1.1.2 Ionizing radiation 
Radiation therapy is the most common cancer treatment after surgery. About 50 % of cancer 
patients receive radiation therapy and it is estimated to constitute 40 % of the curative cancer 
modalities23. Radiation therapy can be used as neo-adjuvant therapy (before surgery) or as 
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adjuvant therapy to kill remaining cancer cells and is administered as external beam radiation 
or as brachytheraphy (internal radiation)23.  
Radiation therapy uses ionizing radiation to deliver electrically charged particles (electrons or 
ions) to the tumor site11. This high energy radiation results in various types of DNA lesions 
(Table 1), either via direct ionization of DNA molecules or via formation of free radicals. Of 
these DNA lesions, DNA double-strand breaks (DSBs) are considered the most lethal12. DNA 
DSBs are mainly repaired via the HR or non-homologous end-joining (NHEJ) DNA repair 
pathways, which are described in more detail in Chapter 1.2. However,  if the damage level is 
beyond repair, cells undergo apoptosis or senescence11. Radiosensitivity of a tumor depends on 
underlying mutations in DNA repair genes, activity of survival pathways and tumor 
suppressors, as well as the tumor microenvironment11. Due to radiation resistance and toxicity 
to normal cells, combination treatments sensitizing cancer cells to ionizing radiation or 
protecting normal tissue hold potential to improve clinical outcomes24. 
1.1.3 Synthetic lethality 
A focus of current cancer research is to find specific molecular mechanisms that cancer cells 
uniquely depend on for survival. The idea behind targeted therapies is that these anti-cancer 
targets are either not expressed in most non-malignant cells, or that they are especially vital for 
cancer cells but not for healthy cells4. Thus, an optimal targeted therapy gives clinicians a large 
therapeutic window to treat cancer. One of the most effective targeted therapy approaches is 
the synthetic lethal therapy (Figure 2)6. 
 
Figure 2. The basic principle 
of synthetic lethality in 
cancer. Synthetic lethality 
can be achieved by mutation 
of two genes (b) or by 
pharmaceutical inhibition of 
“Gene B” in a single mutant 
cell (c). Also overexpression 
of “Gene A” can lead to 
synthetic lethality with 
inhibition of “Gene B” (d)6. 
Reprinted by permission 
from Springer Nature 
Customer Service Centre 
GmbH: Springer Nature, 
Nature Reviews Genetics, 
Synthetic lethality and 
cancer, Nigel J. O’Neil, 
Melanie L. Bailey and Philip 





The term synthetic lethality was first presented in the context of genetics for two genes that, 
when both mutated, are lethal for the organism although mutation of one is harmless25,26. 
Today, the synthetic lethality principle in cancer comes from the realization that cancers are 
often dependent on certain process or pathway due to disturbance of another parallel process, 
for example resulting from a mutation of a gene6,27. Therefore, inhibiting the remaining 
functional pathway will result in cancer cell death (Figure 2). Furthermore, synthetic lethality 
can be expanded to entail conditional synthetic lethality, which means that certain conditions 
such as hypoxia or metabolic changes enable synthetic lethal interactions. On the other hand, 
synthetic cytotoxicity specifies a situation where a targeted therapy results in cell death in cells 
with certain genetic alterations in combination with a DNA damaging agent6. 
The synthetic lethality approach in cancer treatment is best exemplified by PARP inhibitors 
(Figure 3). The breast/ovarian cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2), which 
are commonly mutated in hereditary breast and ovarian cancer, play a key role in HR repair28,29. 
PARP proteins bind DNA single-strand breaks (SSB) and recruit repair factors in several repair 
pathways such as base-excision repair (BER) and nucleotide excision repair (NER)30. 
Consequently, inhibition of PARP impairs the repair of SSBs which will be converted to DSBs. 
However, BRCA1- or 2-mutated cells are unable to repair these DSBs via HR, which renders 
cells deficient in both HR and SSB repair leading to cancer cell death due to unresolved DSB 
damage (Figure 3)6. Moreover, PAPR modulates the replication fork progression, and 
inhibition of PARP results in increased speed of the replication fork elongation, causing 
replication stress31. PARP inhibitors also trap PARP to the DNA, making PARP unable to 
dissociate which interferes with replication and potentiates the cytotoxic effects of PARP 
inhibitors enabling the use of PAPR inhibitors beyond BRCA-mutated cancers32,33. Repair of 
PARP-DNA complexes requires repair pathways such as FA and HR and factors required for 
removal of DNA adducts34. 
 
Figure 3. Principle of the use of PARP 
inhibitors in BRCA-mutated cancers. 
PARP inhibition leads to ineffective 
repair of DNA single-strand breaks 
which are then converted to DNA 
double-strand breaks and repaired via 
HR. BRCA-mutated cells cannot use HR 
which results in cell death. In addition, 
PARP trapping leads to improved 
efficacy of PARP inhibitors6. Reprinted 
by permission from Springer Nature 
Customer Service Centre GmbH: 
Springer Nature, Nature Reviews 
Genetics, Synthetic lethality and cancer, 
Nigel J. O’Neil, Melanie L. Bailey and 





1.1.4 Drug synergism 
Drug combinations are widely used in cancer treatment to increase the therapeutic responses 
and to combat the development of cancer drug resistance. Since new drug combinations can be 
tested only in limited amount of clinical trials and in vitro screens, rational design of drug 
combinations is needed35. Drug synergy in cancer treatment can be achieved by classical 
synthetic lethal interactions by targeting complementary pathways or processes of cancer cells 
with deficiency in a parallel mechanism, as summarized in the previous chapter36. However, 
also targeting the same pathway can result in more complete response than either drug alone 
leading to synergistic effects37. Drug synergy is more than the additive effect of two drugs and 
several mathematical methods have been developed that aim to determine whether a 
combination effect on cancer cell phenotype is truly synergistic and not a mere additive effect 
of two drugs when drug combinations are tested in vitro38. Chapter 3.1 summarizes the method 
used in this thesis to measure drug synergy in cell viability assays. 
In addition to pure in vitro screens, semi-computational methods to predict drug synergies have 
been developed. Example of this is Cancer Drug Atlas, that was successfully used to predict 
drug synergies based on single-compound drug response data matched which corresponding 
molecular mechanism of drug sensitivity37. The benefit of this predictive approach is especially 
highlighted in the ability to detect multi-drug synergies, that are impossible to test with non-
computational methods due to the large number of possible combinations.  
1.1.5 Case: Ovarian cancer 
Ovarian cancer is an example of a highly lethal cancer that lacks effective treatment options. 
More than 50 % of ovarian cancers are detected at a late stage, which partly explains the poor 
overall survival rate of 40 %39–41. Although 80 to 90 % of ovarian cancer patients respond to 
first line therapy, 75 % of them relapse within 18 months with insensitivity to the same 
chemotherapy42. A majority ovarian cancers are defined as epithelial ovarian carcinoma (EOC) 
which can be further divided in histotypes43. High-grade serous ovarian cancer (HGSOC) is a 
histotype that accounts for about 70 % of all ovarian cancer cases and has the worst prognosis44. 
Approximately 15 % of EOC arise from hereditary preposition40. Of these, 75 % are caused by 
mutations in BRCA1 and BRCA245–47. In HGSOC the BRCA1/2 mutation rate can be as high as 
22 %48. In addition, all HGSOC patients are evaluated to have a deficiency at least in one main 
DNA repair pathway49. Due to deficiency in DNA repair genes and mutations in the tumor 
suppressor gene TP53, HGSOC is characterized by high genomic instability, which increases 
the aggressiveness of tumors and development of drug resistance50. On the other hand, in the 
presence of DNA repair deficiencies, the repair capacity of another, complementary, DNA 
repair pathway can be enhanced by overexpression of repair proteins, which contributes to 
treatment resistance49. Mutated TP53 and activation of phosphoinositide 3-kinase (PI3K) 
pathway are common early events in HGSOC51.  
Despite various histological and molecular differences between histotypes, ovarian cancer is 
mostly treated as a single disease. Standard treatment after surgery involves chemotherapy with 
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platinum drugs (cisplatin, carboplatin) and the microtubule-binding agent paclitaxel52. In 
addition, the anti-angiogenic monoclonal antibody bevacizumab is used during, and after, first 
line chemotherapy53. As a second-line therapy, after relapse and platinum resistance, topotecan, 
doxorubicin, etoposide, and gemcitabine (Figure 1)  can be used34. Due to resistance and toxic 
side-effects of the current therapies, targeted and personalized therapies alongside with early 
detection, are urgently needed. A successful example of targeted therapies based on molecular 
characteristics of ovarian cancer is the approval of the PARP inhibitor olaparib for the treatment 
of BRCA1/2 germline mutated ovarian cancers by Food and Drug Administration (FDA) in 
201454,55. To date, two additional PARP-inhibitors, rucaparib and niraparib, are approved for 
the treatment of ovarian cancer56,57. Other PARP inhibitors, veliparib and talazoparib, have not 
been approved for ovarian cancer treatment yet, but their use is under clinical investigation58,59.  
1.2 THE DNA DAMAGE RESPONSE 
The genome is constantly facing endogenous and exogenous insults for example through 
intrinsic DNA replication errors, ROS, ultraviolet (UV) radiation and environmental toxins. 
The DNA damage response (DDR) is an evolutionary conserved signaling cascade that detects, 
signals, and repairs DNA damage in cells while cell cycle progression is halted5. If the damage 
is beyond repair, cell initiates apoptosis in order to avoid chromosomal aberrations, which 
could for example lead to the onset of cancer60. This chapter describes the DDR process, 
highlighting aspects related to the recognition and repair of DNA damage caused by platinum 
and IR treatments, connecting these processes into understanding of synergistic treatment 
opportunities and treatment resistance in cancer discussed in last chapters of this thesis. 
1.2.1 Recognition and signaling of DNA damage 
The components of the DDR can be divided into DNA damage sensors, adaptors / mediators 
and downstream transducers and effectors5. PI3 kinase-related kinases (PIKKs), Ataxia 
telangiectasia and Rad3 related (ATR), ataxia-telangiectasia mutated (ATM) and DNA-
dependent protein kinase (DNA-PK), are key transducers of DNA damage signaling 
orchestrating the control of DNA repair and cell cycle progression (Figure 4)61. Different 
PIKKs are recruited to the DNA damage sites depending on the cell cycle phase and the nature 
of the DNA damage. ATR responds to ssDNA, which is often generated upon replication stress 
deriving from replication impairments61. On the other hand, ATM and DNA-PK are activated 
by DSB formation62.  
In the canonical mode of action, ATR is recruited to replication protein A (RPA) at the ssDNA 
via the ATR-interacting protein (ATRIP)63. RPA is important factor in the protection of ssDNA 
and upon ssDNA formation, RPA readily coats it and protects the ssDNA from degradation 
and from the formation of secondary structures63. ATR is subsequently activated by DNA 
topoisomerase 2-binding protein 1 (TopBP1) or Ewing Tumor Associated Antigen 1 (ETAA1), 
and further phosphorylates the adaptor claspin which mediates the phosphorylation of the 
effectors such as checkpoint kinase 1 (CHK1) which elicits cell cycle arrest at different cell 
cycle checkpoints to allow time for DNA repair64. A complex called 9-1-1, which consists of 
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RAD9, RAD1 and HUS1 proteins, is involved in the TOPBP1-mediated activation of ATR65–
67. 
                 
Figure 4. DNA-PK, ATM and ATR are the main kinases responsible of sensing DNA double-strand breaks and 
single-stranded DNA. They control DNA damage signaling cascades leading to DNA repair, cell cycle control, 
apoptosis, and other cellular responses aiming to maintain the integrity of the genome. Details are described in the 
text. DSB=double-strand break; ssDNA=single-strand DNA. Reprinted from Molecular Cell, 66 (6), Andrew N. 
Blackford, Stephen P. Jackson, ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response, 
801-817, Copyright © 2017, with permission from Elsevier. 
Upon DSB formation, ATM is recruited and activated by the MRN sensor complex which 
consists of double-strand break repair protein MRE11 (MRE11), RAD50 double-strand break 
repair protein (RAD50), and nibrin (NBS1)68. When activated, ATM further phosphorylates 
the histone H2AX at serine 139, forming γH2AX69, and the mediator of DNA damage 
checkpoint 1 (MDC1) which is recruited to γH2AX61. MCD1 further recruits MRN to the 
chromatin, promoting HR, creating a positive feedback loop that amplifies ATM recruitment 
and activation 61. A linker histone H1 is ubiquitinated by E3 ubiquitin ligase ring finger protein 
8 (RNF8)70. This results in the recruitment of another ubiquitin ligase, RNF168, which  
ubiquitinates H2AX, leading in the recruitment of tumor suppressor p53-binding protein 1 
(53BP1) which protects DNA ends from resection via the shieldin complex71–74. ATM-
mediated threonine 68 phosphorylation of CHK2 is a marker for CHK2 activation, which is 
the canonical event downstream of ATM signaling and catalyzes further phosphorylation 
events to elicit cellular responses for DSB damage64.  
The second PIKK involved in DSB repair, DNA-PK, consists of a catalytic subunit (DNA-
PKcs) and a regulatory heterodimer of Ku proteins (Ku70 and Ku80)75. In contrast to ATM, 
DNA-PK is essential in the NHEJ repair of DSBs62. As reviewed by Blackford and Jackson 
(2017), DNA-PKcs is recruited to the DSB and activated at the DNA ends by Ku proteins61. 
Ku proteins and activated DNA-PKcs further recruit and activate other NHEJ core factors 
needed for the ligation process. The interplay between BRCA1 and 53BP1 plays an important 
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role in the regulation of DSB repair pathway choice between HR (Chapter 1.2.2) and NHEJ76 
via mechanisms that are out of the scope of this thesis. Briefly, in G1 phase HR is suppressed 
by 53BP1 via its effector RIF1 which inhibits BRCA1-mediated DNA end-resection required 
for HR77 and by inhibition of BRCA2 recruitment via suppression of BRCA1–Partner and 
localizer of BRCA2 (PALB2) interaction78. On the other hand, in the S/G2 phases BRCA1, 
together with C-terminal binding protein 1 interacting protein (CtIP), antagonizes 53BP1 
promoting HR61.  
The PIKKs have overlapping functions; they can activate multiple repair factors and regulate 
several repair pathways61. Table 2 summarizes DNA repair pathways and what type of damage 
they can repair. HR and NHEJ can both repair double-strand breaks but HR is active only in 
the S and G2 phases since it needs sister chromatid as a template for repair5. On the contrary, 
NHEJ merely ligates resected DSBs together and can therefore repair DNA in any phase of the 
cell cycle5, whereas the FA pathway is a pivotal process in the initiation of ICL repair and it is 
mainly active in S phase79. HR and FA repair pathways, which are key pathways in the repair 
of DNA damage caused by platinum and IR in replicating cells, will be described in more detail 
in the following chapters. 
DDR mechanism Prime DNA damage lesions acted upon 
Direct DNA-lesion reversal UV photo-products, O6 alkylguanine 
Mismatch repair (MMR) DNA mismatches and insertion/deletion loops arising from 
DNA replication 
Base excision repair (BER) and single-
strand break repair  
Abnormal DNA bases, simple base-adducts, SSBs generated 
as BER intermediates, by oxidative damage or by abortive 
topoisomerase I activity 
Nucleotide excision repair (NER) Lesions that disrupt the DNA double-helix, such as bulky 
base adducts and UV photo-products 
Translesion synthesis (TLS) Base damage blocking replication-fork progression 
Non-homologous end-joining (NHEJ) Radiation- or chemically-induced DSBs  
Alternative NHEJ (alt-NHEJ) Repair of DSBs based on microhomology-mediated end-
joining 
Homologous recombination (HR) DSBs, stalled replication forks, interstrand DNA crosslinks 
and abortive Topoisomerase II action 
Fanconi anemia pathway Interstrand DNA crosslinks 
ATM-mediated DDR signaling DSBs 
ATR-mediated DDR signaling ssDNA, resected DSBs 
Table 2. Summary of the main DNA repair pathways and DDR signaling mechanisms and the primary lesions 
they recognize. Homologous recombination and Fanconi Anemia pathway are described in the text in more detail. 
DDR=DNA damage response; DSB=double-strand break; ssDNA=single-strand DNA; UV=ultraviolet; 
SSB=DNA single-strand break. Table adapted by permission from Springer Nature Customer Service Centre 
GmbH: Springer Nature, Nature, The DNA-damage response in human biology and disease, The DNA-damage 
response in human biology and disease, Stephen P. Jackson1 and Jiri Bartek, Copyright © 2009. 
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1.2.2 Homologous recombination 
HR is regarded as an error-free DSB repair mechanism compared to NHEJ, as it uses the sister 
chromatid as a template for repair61. This is the preferred repair pathway for DSBs that occur 
at active replication forks80. HR is a multistep process involving a number of factors but it can 
be separated to following main steps: 1) DNA resection, 2) strand invasion, 3) DNA synthesis 
and 4) resolution (Figure 5)81. HR repair requires both ATM and ATR-mediated signaling as 
both DSB and generation of ssDNA occur during the repair process82.  
                                       
MRN complex localizes to DSBs via yH2AX and MDC1 and initiates the DNA resection by 
its own endolytic cleavage activity, promoted by CtIP83, and by recruitment of endonucleases 
such as Exonuclease I (ExoI) and Bloom helicase (BLM) for 5’- 3’ resection of DNA (step 
1)82. The resection step leads to generation of ssDNA which is coated by RPA. BRCA1 is 
phosphorylated by ATM at DSB sites and works as a scaffolding factor to recruit for example 
the BRCA2-RAD51 complex to the ssDNA, which enables the homology search between 
DNA templates and catalyzes the strand invasion (step 2)84. In this step, RAD51 forms a 
RAD51-nucleoprotein filament with the ssDNA, displacing RPA from the ssDNA85 and 
mediates the connection between the invading DNA and the template DNA, which generates a 
D-loop structure86. Subsequently, the invading DNA is extended by DNA polymerases (step 
3), followed by resolution of possible Holliday junctions and final ligation step (step 4) (Figure 
5).  
Figure 5. Homologous 
recombination repair of DNA 
double-strand breaks. Figure 
illustrates key events and 
factors involved. Details are 
described in the text. 
SDSA=Synthesis-dependent 




Upon DNA damage induction in S phase, dNTPs levels increase about four-fold compared to 
already elevated levels during S phase to support DNA repair synthesis87. As reviewed by Niida 
et al. (2010), this higher demand is reached by increasing the transcription of Ribonucleotide 
reductase (RNR) genes, by subcellular localization of RNR to the nucleus and by concentrating 
dNTPs at the DNA damage sites87. RNR is responsible for catalyzing the generation of 
deoxyribonucleotides from ribonucleotides and consists of the Ribonucleotide Reductase 
Catalytic Subunit M1 (RRM1) and Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) 
or its isoform, RRM2B, which is p53 inducible87.  
1.2.3 The Fanconi Anemia pathway 
The FA pathway recognizes and coordinates the repair of ICLs. It derives its name from the 
Fanconi Anemia disorder, which is a genetic diseases caused by biallelic germline mutations 
in the FA complementation group proteins (FANCA-FANCW)79 and presents as bone marrow 
failure during childhood due to vast genomic instability88. The FA proteins and FA-related 
proteins (FAAPs) initiate the ICL repair which requires the coordination of  NER, TLS and HR 
repair pathways79,89. It consists of; lesion recognition and fork convergence by FA proteins, 
nucleolytic incision and unhooking by NER, lesion bypass by TLS and DSB repair by HR, 
illustrated in Figure 6. 
In the first step of the FA pathway, (a) BRCA1 functions to evict the CMG replicative helicase 
complex, consisting of the Cell division control protein 45 homolog (Cdc45), the 
Minichromosome maintenance proteins 2-7 (Mcm2-7) and the DNA replication complex 
GINS (GINS)90, from the stalled forks allowing one replication fork to approach the ICL (fork 
convergence)91. The ICL is recognized (b) by Ubiquitin like with PHD and ring finger domains 
1 (UHRF1) protein92 and a complex consisting of FANCM, FAAP24 and histone-fold-
containing FANCM-associated proteins MHF1 and MHF293. The BLM helicase promotes the 
recruitment of FANCM to stalled replication forks by interacting with FAAP2494, whereas (c) 
FANCM promotes the checkpoint response via ATR95. Simultaneously, ATR phosphorylates 
the FANCI protein, which acts as on-switch for the FA pathway96. Then, the FANCM-
FAAP24-MHF1-MHF2 complex recruits the FA core complex to the ICL, which in its turn (d) 
ubiquitinates a heterodimer consisting of FANCD2 and FANC1 (ID2 complex)79. The 
monoubiquitination of the ID2 complex results in a conformational change in the complex 
which clamps the FANC1-FANCD2 heterodimer to the dsDNA, stabilizing it97. The ATR-
mediated FANCI phosphorylation maintains FANCD2 ubiquitination, protecting it from 
deubiquitination98. Subsequently, the ID2 complex recruits other FA and HR proteins to the 
damage site99. Next, ubiquitinated FANCD2 together with SLX4 structure-specific 
endonuclease subunit, recruit structure-specific nucleases (SSEs) to (e,f) unhook the ICL, 
which generates a DSB in the opposite strand from the ICL100–102. Consequently, one DNA 
stand is still tethered to a nucleotide and in this strand the ICL is (g) bypassed by TLS, which 




Figure 6. Overview of the repair of ICL damage by the Fanconi Anemia pathway. Details are described in the text. 
Republished with permission of Annual Reviews, Inc., from The fanconi anemia pathway in cancer, Niraj, Joshi; 
Färkkilä, Anniina; D'Andrea, Alan D, Volume 3, Issue 1, Copyright © 2019; permission conveyed through 




The DSB generated during ICL unhooking can be repaired via HR, NHEJ (also referred as 
canonical NHEJ; C-NHEJ), alternative NHEJ (alt-NHEJ) or single-strand annealing (SSA)79. 
In S phase, DSB repair is initiated by the (h) resection of DSB ends with the DSB resection 
machinery104. If the resection is minimal, the break can be repaired via alternative NHEJ (alt-
NHEJ) utilizing polymerase θ (POLθ), which is error-prone79. However, (i) extensive resection 
mediated by BLM, Exonuclease 1 (EXO1), DNA replication ATP-dependent helicase/nuclease 
DNA2 and CtIP leads to longer ssDNA stretches coated by RPA79. The RPA coating is 
subsequently replaced either by RAD52 to mediate repair via SSA or (j) RAD51 to promote 
(k,l) HR79. Briefly, in SSA homologous repeats that flank the DSB are annealed together which 
forms an intermediate synapsis105. Following this, ssDNA tails are processed by 
endonucleolytic cleavage and remaining gaps are filled by polymerases and ligated. In contrast 
to HR, SSA causes deletions and rearrangements of the DNA, and increases genomic 
instability, however SSA can be preferred over HR in case of dysfunctional HR, or if the DSB 
occurs in early of mid-S phase far prior replication fork when sister chromatid is not present105.  
1.2.4 Replication stress 
The high fidelity of DNA replication ensures that the genome is duplicated correctly from one 
cell division to another. Replication stress is defined as transient replication blockage or 
slowdown in response to DNA lesions, aberrant replication fork structures and other replication 
fork obstacles as well as and oncogene activation in cancer106,107. Genomic instability is a cause 
and consequence of replication stress and, consequently, cancer cells are often characterized 
by increased levels of replication stress108. Likewise, cancer treatments such as platinum and 
IR induce replication stress by DNA damage induction and by interfering with DNA 
replication.  
Replication stress leads to the activation of the replication stress response to stabilize and restart 
the replication fork and to maintain genomic stability106. The replication stress response is 
activated by ssDNA, which is generated upon replication fork stalling by the uncoupling of the 
replicative helicase from DNA polymerases109. Phosphorylation of ATR by RPA elicits the 
ATR-CHK signaling cascade which leads to cell cycle arrest and other cell-protective events 
described in Chapter 1.2.1. However, recent findings suggest that already replication fork 
stalling is able to activate ATR-CHK1 pathway in 9-1-1/TOPBP1-dependent manner before 
generation of excess ssDNA and RPA coating, which functions only after the fork stalling to 
amplify the ATR-CHK1 activation110. Importantly, activated ATR reciprocally phosphorylates 
the chromatin-bound RPA at serine 33, which promotes RPA hyperphosphorylation by CDKs 
and limits the release of extensive ssDNA111. Notably, in response to replication stress H2AX 
is phosphorylated at serine 139 in ATR dependent but not ATM independent manner, in 
contrast to DSBs, leading to recruitment of other DDR factors such as proliferative nuclear 
antigen (PCNA), BRCA1 and 53BP1 at stalled replication forks112.  
High levels of replication stress can lead to fork collapse and breakage generating DSBs, i.e. 
replication catastrophe, which is a lethal event for a cell113. Even in physiologically normal 
levels of initial replication stress, replication catastrophe can occur if the replication stress 
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response fails to protect the stalled fork, for example in the absence of RPA114. RPA excess in 
the cell attenuates the replication catastrophe and acts as a buffer against lethal threshold of 
replication stress by increasing tolerance to ssDNA (Figure 7). Interestingly, ATR protects cells 
against the exhaustion of RPA during replication stress by suppressing global origin firing. 
Conversely, depletion of ATR increases ssDNA formation depleting the available RPA pool 
and increasing fork breakage114.  
In addition, studies using hydroxyurea treatment have demonstrated that the FA pathway is 
also activated in high levels of replication stress without ICL damage79. On the other hand, in 
response to low levels of replication stress, FANCD2 and FANCI seem to have FA pathway-
independent roles mediated by ATR, resulting in suppression of firing of dormant and new 
origins, which highlights the diverse roles of the FA pathway proteins in the maintenance of 




Figure 7. RPA protects ssDNA from breakage and degradation increasing the replication stress tolerance113. 
Physiological levels of ssDNA are generated by replicative events such as the lagging DNA strand and R-loops as 
well as endogenous replication stress (green). Checkpoint inhibitors and replication inhibitors such as hydroxyurea 
(HU) lead to large quantities of ssDNA generation and can cause replication catastrophe by RPA exhaustion. 
Ionizing radiation (IR), ultraviolet (UV) radiation, topoisomerase poisons and oncogene activation can further 
increase ssDNA formation and replication stress (RS). DSB=double strand break; NER=nucleotide excision 
repair. Reprinted from Molecular Cell, 66 (6), Luis Toledo, Kai John Neelsen and Jiri Lukas, Replication 





1.3 CX3CR1: EMERGING ROLES FOR A CHEMOKINE RECEPTOR 
C-X3-C motif chemokine receptor 1 (CX3CR1/fractalkine receptor) is heptahelical receptor 
belonging to the G protein-coupled receptor (GPCR) superfamily115. The binding of the natural 
ligand for the receptor, C-X3-C motif chemokine ligand 1 (CX3CL1/fractalkine)116,117, leads 
to the activation of the Gi protein which triggers several major intracellular signaling events 
such as PI3K/Protein kinase B (Akt) and Mitogen-activated protein kinase 
(MAPK)/Extracellular signal-regulated kinase (ERK) pathways, depending on the cellular 
context (Figure 8)118–123. Moreover, CX3CR1 can transactivate the epidermal growth factor 
receptor (EGFR/ErbB-1) and human epidermal growth factor receptor 2 (HER2/ErbB-2)123–
125. Fractalkine is the only chemokine in the structural C-X3-C group of chemokines and exists 
in both membrane-bound and soluble forms 116. Unlike other chemokines, fractalkine 
selectively binds to CX3CR1126. CX3CR1 signaling promotes cell adhesion via the membrane-
bound ligand and migration, proliferation, anti-apoptosis, angiogenesis and epithelial-
mesenchymal transition via its soluble ligand127.  
Owing to the canonical role of chemokines, fractalkine and CX3CR1 were discovered due to 
their role in inflammation. Fractalkine was first reported to be expressed by inflammatory 
endothelial cells, in response to inflammatory cytokines, to promote migration and invasion of 
leukocytes that, subsequently, were demonstrated to express CX3CR1115,116,128. In its 
membrane-bound form, fractalkine promotes adhesion of CX3CR1 positive leukocytes to the 
inflamed endothelium116. In addition, CX3CR1 signaling has been connected to survival of 
monocytes129. Furthermore, the CX3CL1/CX3CR1 axis has a pivotal role in the brain in the 
elimination of damaged CX3CL1-expressing neurons by CX3CR1-expressing microglia, in 
neuronal protection and plasticity as well as neurogenesis130. CX3CL1/CX3CR1 signaling is 
involved in the pathogenesis of several cancers and other conditions such as multiple sclerosis, 
neuronal pain, and reperfusion injury after myocardial infarction130–132. 
In addition to leukocytes and the central nervous system (microglia, astrocytes, and 
hippocampal neurons)133, CX3CR1 is also expressed in osteoclasts134 and in cancer cells130, 
and its expression is induced by fractalkine, interleukin 10, interferon γ and hypoxic 
conditions120,135,136. Besides the brain, inflammatory endothelium and fibroblasts, CX3CL1 
mRNA is found in wide range of tissues such as heart, lung, kidney, intestines, skeletal muscles 
and some epithelial cells116. Importantly, both CX3CR1 and CX3CL1 can be expressed by the 
same cell, and CX3CL1 can induce its own expression and that of CX3CR1121. Thus, cells can 




Figure 8. CX3CR1 activation by CX3CL1 can lead to the activation of several signaling pathways depending on 
the cellular context via Gi protein or by transactivation of the epidermal growth factor receptor (EGFR) by matrix 
metalloproteinases, such as ADAM17, that release EGFR-activating ligands126,127,130. Examples of proteins 
activated by these pathways are written in brackets and potential cellular outcomes, many of which are related to 
pro-tumorigenic phenotypes, are written in blue. After G protein activation, β-arrestin is recruited, internalizing 
the receptor into early endosomes which can result in the termination of the CX3CR1-induced signals. However, 
β-arrestins can elicit further signaling events and G proteins can continue to be active in in intracellular 
compartments
137–139
. Activation of CX3CR1 induces also calcium mobilization, but there is evidence that this 
cannot happen without active an Gαq protein
140. ADAM17=A disintegrin and metalloproteinase 17; HB-
EGF=heparin-binding epidermal growth factor; TGF-α=Transforming growth factor α; EGFR=Epidermal growth 
factor receptor; HER2= human epidermal growth factor receptor 2; RAS=Ras GTPase; ERK=Extracellular signal-
regulated kinase; FAK=Focal adhesion kinase; JAK2=Janus kinase 2; STAT3=Signal Transducer And Activator 
Of Transcription 3; EMT=Epithelial-mesenchymal transition. Figure based on reviews by Korbecki et al. 2020, 
White et al. 2012 and Rivas-Fuentes et al. 2020 126,127,130. Created with BioRender.com. 
1.3.1 CX3CR1 in cancer 
CX3CR1 is involved in cancer invasion and metastasis125,141, proliferation and survival142,143 
as well as modulation of the tumor microenvironment in several cancers144–148. The 
CX3CL1/CX3CR1 axis contributes to the pro-cancer phenotype of for example ovarian 141, 
breast124, prostate125, colorectal149, testicular145, pancreatic150, lung151, gastric cancer152, B cell 
malignancies153 and glioblastoma154. CX3CR1 expression has been associated with poor 
patient outcomes in ovarian cancer141 and clear cell renal cell carcinoma155. CX3CR1 is 
upregulated in primary and metastatic EOC, but it is almost absent in normal ovarian surface 
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epithelium156. Furthermore, CX3CR1 expression increases over the course of ovarian cancer 
progression141 and is expressed early on during pancreatic carcinogenesis potentially 
promoting invasiveness157, indicating that CX3CR1 might be involved in the early steps of 
tumorigenesis and promote aggressiveness of cancers. 
However, CX3CR1 expression is also associated with better prognosis in some cancers, such 
as colorectal cancer149, hepatocellular carcinoma158 as well as pancreatic ductal 
adenocarcinoma157. Interestingly, fractalkine signaling can have a dual role in the spread of 
cancer; if CX3CL1 is expressed distant from the tumor site it promotes metastasis of cancer 
cells that express CX3CR1125,141, but if CX3CL1 is expressed locally at tumor site, it anchors 
cancer cells and prevents metastasis149,158. 
Regarding the involvement of CX3CL1/CX3CR1 in the tumor microenvironment, CX3CL1 
has been found to promote recruitment of CX3CR1-expressing tumor infiltrating macrophages 
(TAMs) in testicular germ cell cancer145, endometrial carcinoma146, skin cancer148 and 
pancreatic ductal adenocarcinoma147, thereby contributing to the tumorigenic cancer 
microenvironment. On the other hand, CX3CL1 can attract CD8+ T cells and NK cells 
resulting in a better prognosis for gastric adenocarcinoma159. Furthermore, the 
CX3CL1/CX3CR1 axis can modulate the cancer microenvironment by promoting 
angiogenesis, as seen in in multiple myeloma144.  
CX3CR1 activation can mediate proliferation of cancer cells via several mechanisms (Figure 
8). For example in pancreatic cancer, CX3CL1/CX3CR1 induces the upregulation of anti-
apoptotic molecules and downregulation of pro-apoptotic molecules via activation of Akt160. 
In addition, CX3CR1 signaling can promote cancer cell proliferation and cell cycle progression 
possibly via activation of the Akt pathway in ovarian cancer161 and via the Akt/Nuclear factor 
NF-kappa-B (NFκB) pathway in pancreatic cancer160. Moreover, CX3CR1 can transactivate 
the EGFR pathway in breast cancer124. Interestingly, activation of CX3CR1 in pancreatic 
carcinoma can increase glucose uptake and lactate secretion via induction of Hypoxia-
Inducible Factor-1α (HIF-1α) in a PI3K/MAPK-dependent manner and thus favors anaerobic 
glycolysis for cell proliferation162. Finally, CX3CL1/CX3CR1 has been seen to  promote 
epithelial-to-mesenchymal (EMT) transition in ovarian cancer and prostate cancer136,163. 
In summary, the CX3CL1/CX3CR1 pathway can either have pro- or anti-tumor effects 
depending on the tissue origin of the cancer and the pathways activated, co-expression status 
of both ligand and receptor, and the effect of tumor microenvironment. When dissecting the 
involvement of the CX3CL1/CX3CR1 axis in cancer, it is important to separate the 
immunomodulatory functions of CX3CL1 in the tumor microenvironment and the role of 






1.3.2 CX3CR1 in DNA repair 
In 2018, a study suggested that CX3CR1 increases resistance to DNA damaging treatments in 
cancer cells164. Xie et al. reported that CX3CR1 knockdown by small interfering RNA (siRNA) 
treatment sensitized OC cell lines to ionizing radiation, cisplatin, and carboplatin in long term 
proliferation assays164. Furthermore, knockdown of CX3CR1 inhibited phosphorylation of 
ATM, DNA-PKcs, CHEK1 and CHEK2, and delayed IR-induced γH2AX foci formation, 
which resulted in high amount of DSBs164. The regulatory effect of CX3CR1 on these DDR 
factors was attributed to reduced protein levels of RAD50 and disturbance of MRN complex164. 
In vivo, CX3CR1 knockdown and ionizing radiation revealed an organ-specific synergy in 
HGSOC tumor reduction. Notably, in this xenograft model using SKOV3 cell line, CX3CR1 
knockdown alone significantly reduced omental metastasis164, unlike in a syngeneic ovarian 
carcinoma mouse model published earlier141. Reduced omental metastasis was partially 
explained by reduced uptake of fatty acids from omental adipocytes by cancer cells upon 
CX3CR1 knockdown164. Importantly, high CX3CR1 mRNA expression significantly 
correlated with worse overall survival of ovarian cancer patients that were treated with 
platinum drugs and other DNA damaging agents164. Taken together, CX3CR1 has an emerging 
role in the regulation of the DDR response in cancer cells and CX3CR1-mediated enhanced 
DNA repair capacity could confer proliferative advantage in cancers that display genomic 
instability and resistance to DNA damaging agents. 
1.3.3 CX3CR1 as a therapeutic target 
About half of all FDA approved drugs currently in the market target GPCRs due to their overall 
druggability and involvement in a myriad of diseases137,165. Chemokine receptors are attractive 
therapeutic targets due to their role in inflammation and immunity and efforts have been made 
to pharmaceutically target various chemokine receptors in different diseases166,167. For 
example, the CCR5 antagonist Maraviroc is used in the clinic in a combination treatment of 
HIV and its use in cancer is also under evaluation168,169. There are currently several inhibitors 
or antibodies targeting chemokine receptors in clinical cancer trials170 
(https://www.clinicaltrials.gov/) and two in use (the monoclonal CCR4 antibody 
Mogamulizumab and the CXCR4 inhibitor AMD3100) for hematological cancers166,170.  
Since CX3CL1/CX3CR1 signaling is involved in pathogenesis of several diseases, but supports 
few normal processes in adults, several drugs targeting CX3CR1 or CX3CL1 are under 
development. An antibody targeting CX3CL1 (E6011; Eisai Pharmaceuticals)171 has shown 
efficacy in a Phase 2 clinical trial of rheumatoid arthritis172. KAND567 is the first selective 
small molecule inhibitor targeting CX3CR1 (Kancera AB)173,174 and it has successfully passed 
clinical phase 1 trial with healthy volunteers175. Furthermore, an anti-CX3CR1 nanobody (BI 
655088; Boehringer/Ablynx)176 has recently been evaluated in Phase 1 trial (NCT02696616) 
and it inhibits atherosclerotic plaque formation in mice176. Due to the selectivity and clinically 





The small molecule CX3CR1 inhibitor KAND567 (previously AZD8797)173,174 was used to 
inhibit CX3CR1 in the studies included in this thesis. KAND567 was the first potent and 
selective inhibitor of CX3CR1 to be published173,174. KAND567 was functionally characterized 
by Cederblad et al. (2016) who showed that KAND567 is a negative allosteric modulator of 
CX3CR1 but the exact binding site is not known174. KAND567 binds CX3CR1 in a non-
competitive manner and increases the dissociation of CX3CL1 from CX3CR1, eventually 
displacing CX3CL1. This displacement was hypothesized to be conferred via uncoupling of 
the G protein from CX3CR1 upon KAND567 binding. KAND567 antagonized CX3CL1-
induced G protein signalling in isolated Chinese hamster ovary (CHO) cell membranes stably 
expressing human CX3CR1 with an IC50 value of 340 nM, when 2 nM CX3CL1 was used, 
and prevented the CX3CL1/CX3CR1-mediated capture of human blood leukocytes to 
endothelial cells with a similar IC50174.  
Interestingly, Cederblad and colleagues showed that KAND567 potentiates CX3CL1-mediated 
β-arrestin recruitment at low concentrations, therefore acting as positive allosteric modulator 
in this assay174. In contrast, high concentrations of KAND567 almost totally abolished the 
CX3CL1-induced β-arrestin recruitment. This duality was attributed to the fact that lower 
concentration of KAND567 is needed to bind CX3CR1 than to displace CX3CL1 from the 
receptor. In this context, the KAND567 concentration conveying agonistic function in the β-
arrestin assay was comparable to the concentration of KAND567 receptor-binding, and the 
concentration eliciting antagonist function was similar to the concentration of KAND567-
mediated CX3CL1 displacement. It was therefore suggested that when both KAND567 and 
CX3CL1 are bound to CX3CR1, β-arrestin recruitment is potentiated. Furthermore, KAND567 
alone did not induce β-arrestin recruitment. However, KAND567 alone at high concentrations 
induced a dynamic mass redistribution (DMR) response which was reduced with the addition 
of pertussis toxin. DMR assay is a label-free technique to study GPCRs based on an optical 
biosensor that detect changes in cellular morphology and adhesion as well as cytoskeletal 
rearrangement177.  Change in DMR upon KAND567 indicates that binding of KAND567 to 
CX3CR1 induces cellular responses that result in mass relocation. Therefore, KAND567 has 
partial agonist functions which were suggested to be mediated via CX3CR1. However, CHO 
cells without CX3CR1 expression elicited a mild increase in DMR response and a 10-fold 
higher concentration of KAND567 was needed for this agonist effect on DMR than for 
KAND567 to abolish CX3CL1 binding174. 
KAND567 has a good oral availability173 and further in vivo studies have showed efficacy of 
KAND567 in attenuating multiple sclerosis in mice with calculated effective IC50 mean 
concentration of 2 µM178 and suppressing inflammation179,180. In addition, KAND567 shows 
cardioprotective effects in rodent disease models181 and after successfully passing Phase 1, is 
now under phase II development in myocardial infarction175, and in a phase II study for Covid-
19-related hyperinflammation indications (EudraCT: 2020-002322-85). 
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1.4 PFKFB3: A BIFUNCTIONAL ENZYME AT THE CROSSROADS OF 
METABOLISM AND DNA REPAIR 
Altered metabolism is a hallmark of cancer3 and high rate of glycolysis, the conversion of 
glucose to pyruvate to produce high energy products ATP and NADP, is characteristic to many 
tumors182. Although oxidative phosphorylation is a more efficient way to produce energy, 
tumor cells often prefer the glycolytic pathway even in the presence of oxygen—this 
phenomenon is referred to as the “Warburg effect”183. The reason for cancer cells to prefer 
glycolysis over mitochondrial ATP production, although around 18-fold lower in efficiency, is 
attributed to the production of glycolytic intermediates that can be used in the biosynthesis of 
macromolecules and organelles required for tumor growth184. Another reason for favoring 
glycolysis is hypothesized to be an establishment of low pH environment via lactate 
production, that could cause apoptosis in surrounding non-malignant cells expressing 
functional p53 protein185. This metabolic switch in cancer cells is achieved by activation of 
oncogenes and inactivation of tumor suppressors186,187.  
In the glycolysis (Figure 9) the bifunctional metabolic enzymes, 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatases (PFKFBs), play a key role by synthesizing and degrading 
fructose-2,6-bisphosphate (F2,6BP), which is an allosteric activator of Phosphofructokinase 1 
(PFK-1)188. PFK-1 is a rate-limiting enzyme in glycolysis and can be negatively regulated by 
ATP when high level of energy is no longer needed189. However, abundant F2,6BP can surpass 
this negative feedback loop, enhancing glycolysis and consumption of glucose. Thus, positive 
regulation of F2,6BP, for example by oncogenes, is connected to pro-cancer phenotype of 
cells190. PFKFB3, one of the PFKFB enzymes regulating the production of F2,6BP, possesses 
a dominant kinase function over its phosphatase activity, differing form the other isoforms 
PFKFB1, 2 and 4188. Unlike other PFKFBs, PFKFB3 is an inducible isoform promoted by 
mitogenic stimuli, hypoxia, inflammation and oncogenic transcription factors191–193, indicative 








Figure 9. Glycolysis converts glucose 
to pyruvate to produce energy in the 
form of ATP and NADP. Fructose-
2,6-bisphosphate (F2,6BP) is 
degraded and synthetized by 6-
phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFKFB) enzymes 
from fructose-6-phosphate (F6P). 
F2,6BP activates 6-phosphofructo-1-
kinase (PFK-1) enzyme which 
catalyzes the conversion of F6P to 
fructose-1,6-bisphosphate (F1,6BP). 
F1,6BP is converted then to 
glyceraldehyde 3-phosphate and 
dihydroxyacetone phosphate (DHAP) 
by aldolase. DHAP and G3P can be 
interconverted. Following this, G3P is 
converted to pyruvate via further 
enzymatic steps summarized well by 
Regina Bailey (2020)194. Puryvate can 
enter Tricarboxylic acid cycle (TCA) 
in mitochondria or be converted to 
lactate in the absence of oxygen.  




1.4.1 PFKFB3 in cancer 
PFKFB3 is under regulation of several oncogenes and oncogenic processes195. Ras signaling, 
which is one of the major oncogenic pathways connected to cancer transformation, regulates 
glycolysis via PFKFB3, and the activity of PFKFB3 has been shown to be necessary for ras-
mediated transformation of cancer cells196. Notably, in ras-transformed mouse lung fibroblasts 
PFKFB3, but not other PFKFB enzymes, was necessary for the Ras-mediated growth of 
tumors196. The link between Ras and PFKFB3 may be mediated by HIF-1α, as shown in 
glioblastoma cells197. In addition, mechanistic target of rapamycin (mTOR) signaling has been 
shown to upregulate PFKFB3 in acute myeloid leukemia, without affecting the levels of other 
PFKFB isoforms198. Furthermore, PFKFBs are upregulated by the overexpression of the MYC 
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oncogene199 and PFKFB3 can be positively regulated by the estrogen receptor (ER)200 and 
HER2 signaling192. The tumor suppressors p53 and Phosphatase and Tensin Homolog (PTEN) 
suppress the expression of PFKFB3, which supports the evidence of PFKFB3 as a cancer 
specific modulator of energy metabolism201,202. 
PFKFB3 is overexpressed, or involved, in multiple cancers including ovarian cancer203, breast 
cancer204,205, pancreatic cancer206, colon cancer204,207, gastric cancer206, lung cancer208, 
osteosarcoma209, cervical cancer203, hepatocellular carcinoma210, and nasopharyngeal 
carcinoma211, among others195, and its expression correlates with poor prognosis195. PFKFB3 
is often linked to cancer progression via its canonical role in the glycolysis, which has been 
reported to stimulate for example cancer proliferation, survival, invasion, migration, and 
angiogenesis195. However, PFKFB3 also localizes to the nucleus212, apart from its role in 
glycolysis, which has evoked an interest in putative nuclear roles of this enzyme. Yalcin and 
colleagues first reported that by localizing to the nucleus, PFKFB3 drives cell proliferation via 
upregulation of CDKs and cyclins without affecting glucose metabolism212. Following this, 
PFKFB3 was seen to regulate p27 via CDK-1 and halt G1/S transition213. During this thesis 
work, increasing number of reports on the involvement of PFKFB3 in DNA repair have been 
published and they will be discussed in Chapter 5.2. 
1.4.2 PFKFB3 as a therapeutic target 
PFKFB3 is a promising target for therapeutic intervention in cancer191 and several small 
molecule inhibitors targeting PFKFB3 have been developed195,214. 3PO is a widely used 
PFKFB3 inhibitor used as a tool compound to study the function of PFKFB3215. It attenuates 
tumor growth in vivo215; however, it does not inhibit the kinase activity of PFKFB3216 and was 
recently shown to not bind PFKFB3 despite inhibiting glycolysis217. Moreover, 3PO has poor 
pharmacokinetic properties, which limits its clinical use215. PFK-158 is an improved derivative 
of 3PO that shows efficacy in preclinical cancer models and it has shown no serious side effects 
in a phase I study218–222, however despite advertised as PFKFB3 inhibitor, it does not target the 
enzymatic activity of PFKFB3223. Furthermore, N4A and YN1 were developed by structure-
based design along with the discovery of the crystal structure of PFKFB3, and show inhibition 
of PFKFB3, suppression of glycolysis, and apoptosis of cancer cells in vitro but they are not 
isoform-selective for PFKFB3224. Another PFKFB3 inhibitor AZ67, was developed by 
AstraZeneca; it is a potent PFKFB3 inhibitor but also displays inhibition of PFKFB1 and 2, 
although with lower potency216,223. Taken together, despite yet unsuccessful, there is a vast 




2 RESEARCH AIMS 
The overall aim of this thesis was to characterize the role of CX3CR1 and PFKFB3 in the 
DNA damage response and to evaluate the potential of combining CX3CR1 and PFKFB3 
inhibition (by KAND567 and KAN0438757, respectively) with DNA damaging cancer 
treatments. Specific aims of the papers were: 
 
I. To investigate the mechanistic role of PFKFB3 in DNA repair following ionizing 
radiation and to develop a selective PFKFB3 inhibitor (Paper I) 
 
II. To investigate the potential of blocking ovarian cancer cell proliferation by inhibition 
of CX3CR1 (Paper II) 
 
III. To elucidate the role of CX3CR1 in the DNA damage response upon platinum 
treatments and assess the synergistic potential of KAND567 with platinum drugs in 
cancer cells (Paper III)  
 
IV. To assess the role of PFKFB3 in the repair of platinum-induced damage and to 







3 METHODOLOGICAL APPROACHES 
In this chapter the general aspects of some of the key methods applied in this thesis work are 
presented and discussed. Detailed protocols can be found in the attached research papers. 
3.1 DRUG SYNERGY STUDIES 
Viability studies assessing drug synergies in this thesis were performed by cell viability 
measurements based on resazurin (7-hydroxy-10-oxidophenoxazin-10-ium-3-one, sodium). 
Resazurin in a blue dye that will be enzymatically converted to a highly fluorescent red product, 
resorufin, in viable cells and can be measured by an emission maximum of 590 nm on a 
fluorescence plate reader225. The drawback of this method is that cells that are proliferatively 
slower will require more time to convert the substance and thus the incubation time must be 
optimized for each cell line. Moreover, it might be challenging to separate cells that are 
irreversibly apoptotic from the ones that have merely arrested in cell cycle and slowed down 
their metabolism, thus a long measurement time point may be needed. Resazurin can also be 
toxic to the cells itself, which limits long-term measurements225.  
Dose-response matrix viability values for two compounds were used to calculate delta scores 
(synergy scores) using the Zero Interaction Potency (ZIP) model226 with Synergy Finder 
(https://synergyfinder.fimm.fi)227. ZIP model compares the expected value of a drug 
combination (additive effect with no additional potency) to the observed values to calculate 
delta scores. The summary synergy score is derived from an average delta score divided by the 
dose-response matrix values. A synergy score between 0 and 10 indicates that the drug-
interaction is likely to be additive and a summary synergy score above 10 indicates likely 
synergistic effect. 
3.2 COLONY-FORMATION ASSAY 
Colony-formation assay measures the long-term proliferation capacity of a single cell after drug 
treatment and drug washout. The idea is to seed cells at so low density that the colonies growing 
from single cells can be visualized. Colony-formation assay can help to determine if cells are 
able to continue growing after drug washout, i.e., if the effect of a drug is irreversible on cell 
survival after certain treatment days. Colony-formation assays can be performed also for 
example upon siRNA knockdown of a target. One drawback of this method is that it is 
challenging to seed exactly the same number of cells per well due to the low seeding density 
which can affect the number of colonies detected in the end of the experiment. Moreover, 
sometimes cells tend to concentrate in the middle of the wells of the cell culture plates, which 
makes it hard to separate single-cell colonies. Proper mixing of the cell suspension and careful 
pipetting of the cells in the wells as well as minimizing the disturbances in the incubator 
improves the equal distribution of cells in the wells. The distribution of cells and whether they 
form good visual colonies depends also on the characteristics of the cells as some cells migrate 
and form elongated shapes that are not optimal for the visualization of the colonies. Moreover, 
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colony-formation assay requires good attachment of cells on the cell culture plates and thus 
cannot be performed with suspension cells. 
3.3 SUBCELLULAR PROTEIN FRACTIONATION  
The fractionation of proteins into soluble and chromatin-bound fractions is a useful technique 
to study the chromatin association of proteins and complementary to the detection of nuclear 
damage foci using a confocal microscopy. In this technique protein lysates are first treated with 
a mild extraction buffer to extract soluble proteins, followed by careful washes of the 
chromatin-bound fraction to avoid contamination between fractions. In the last step, an 
enzymatic separation of chromatin-bound proteins is performed to yield the chromatin fraction. 
For normalization, equal cell numbers were harvested instead of protein quantification which 
allowed us to compare protein amount between cell lines. As the protocol contains multiple 
washing and resuspension steps, it is sometimes difficult to obtain equal sample amounts, 
resulting in experimental failures. Equal amount of protein loading in the immunoblots as well 
as fraction purity was controlled by histone 3 for chromatin-bound fraction and tubulin for 
soluble fraction.  
Another drawback of this method is that purely membrane bound proteins, such as CX3CR1, 
will not be included in neither fraction unless internalized to the soluble fraction in endosomes 
or tightly associated with chromatin. Moreover, band intensities of the following immunoblot 
of soluble and chromatin-bound fraction are not directly comparable since, due to technical 
reasons, chromatin-bound fraction is more concentrated in the sample preparation. 
Nevertheless, since we were mostly interested in the chromatin fraction, using soluble protein 
fraction as a control, this technique gave us valuable information on the chromatin-association 
of proteins upon different treatment conditions. Moreover, this technique allows investigation 
of chromatin-recruitment of proteins that do not have optimal antibodies available for 
microscopy studies. 
3.4 DETECTION OF NUCLEAR REPAIR FOCI BY CONFOCAL MICROSCOPY 
The confocal microscopy studies in this thesis, besides measuring total nuclear intensity, 
focused on detecting nuclear damage foci of DNA repair proteins that are formed at the DNA 
damage sites228. By counting the foci numbers per cell and percentage of foci positive cells 
relative to the vehicle conditions by the CellProfiler software (www.cellprofiler.org), we were 
able to determine if the foci formation of a certain protein was impaired or induced upon 
treatment conditions. To visualize the nuclear foci better, in situ subcellular fractionation with 
the cytoskeletal extraction (CSK) buffer was used to remove cytoplasmic and nuclear soluble 
proteins229. A limitation in confocal studies is sometimes the lack of antibodies recognizing the 
endogenous protein or unspecific antibodies. To avoid false positive staining, siRNA mediated 
knockdown was performed to assure specificity of the antibodies not previously validated for 
confocal microscopy. Furthermore, antibodies were also used in immunoblot experiments 
which increases the validity as same results were obtained in two complementary techniques. 
Furthermore, to avoid species cross-reactivity of secondary antibodies, highly cross-absorbed 
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antibodies were used in the experiments as well as confirmational single-stainings when 
necessary. 
3.5 GENERATION OF KNOCKDOWN CELL LINES BY LENTIVIRAL 
TRANSDUCTION 
Knockdown cell lines were generated by introducing short hairpin RNA (shRNA) sequences 
targeting CX3CR1 and PFKFB3 in cancer cells by lentiviral transduction, to validate the 
findings seen upon CX3CR1 and PFKFB3 inhibition with KAND567 and KAN0438757. A 
limitation of the method used was that the knockdown of the targets was constitutive. Since 
constitutive knockdown is present in the cells constantly, it can create a selection pressure for 
cells that survive without the target (escape cells) which may influence experimental outcomes 
despite antibiotics selection, whereas inducible knockdown can be switched on at the start of 
the experiment. Moreover, when knockdown is constitutive, some cells may not survive the 
knockdown at all if the knockdown is complete and cells depend on the target for survival. 
Knockdown levels were quantified using quantitative RT-PCR and Western blot, and cells 
transduced with non-targeting hairpins (scrambled sequences) were used as a control to rule 
out the general effects of lentiviral transduction on cells. 
3.6 DNA FIBER ASSAY 
The DNA fiber assay enables the microscopic visualization of DNA replication in molecular 
level by labeling replicating DNA by one or several different DNA-incorporating dyes230. The 
length of these labeled DNA fibers allows us to determine different parameters such as the 
DNA track length, replication fork speed and replication fork re-start, depending on the 
protocol applied. The preparation of DNA fibers in this thesis work was performed by 
“spreading” the DNA on a positively charged microscopic slide which is a fast technique 
allowing many samples to be processed at the same time and requires less materials compared 
to alternative techniques. However, the spreading technique yields unaligned DNA fibers, 
which complicates the analysis of some parameters such as inter-origin distance and new origin 
firing230. In DNA spreading technique it is important to select areas for imaging with less DNA 
crossings which makes the image acquisition more laborious. Alternative methods, DNA 
“combing” and DNA “stretching”, result in a set of unidirectional DNA fibers which facilitates 
the analysis of more complicated parameters and make the determination of DNA fork speed 
more accurate230.  
To improve the throughput of the measurement, cells were synchronized with aphidicolin 
(Papers III and IV) enabling the recording of as much replicating DNA as possible. A 
drawback of using aphidicolin is that it causes replication stress itself231 which could affect the 
results. At least 100 unidirectional forks labeled with both 5-Chloro-2′-deoxyuridine (CldU) 
and 5-Iodo-2′-deoxyuridine (IdU) were measured for every condition using Fiji software232 and 
the speed of the replication fork was determined from the length of the DNA fiber by 
conversion 1 μm = 2.59 kb. 
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3.7 FLOW CYTOMETRY ANALYSIS OF CELL CYCLE PROGRESSION OF 
REPLICATING CELLS 
In Paper III and IV we were interested how replicating S phase cells progress in cell cycle 
upon our treatment conditions. Thus, we used a technique where we first synchronize cells to 
G1/S boundary and then release them in media containing (5-Ethynyl-2′-deoxyuridine) EdU 
for 45 min to allow cell cycle to proceed to early S phase simultaneously labeling replicating 
cells that then can be traced233,234. Performing drug treatments post-EdU labeling allowed us to 
decipher how cells that have been treated in S phase proceed in cell cycle by fixing the cells at 
certain time points after treatment. To visualize EdU-labeled cells, Click-iT labeling was 
performed after fixation with 70 % ethanol by linking fluorescently labeled azide (ATTO 647 
azide) to an alkyne group of EdU by copper-catalyzed Click chemistry reaction233. In addition, 
cells were stained with propidium iodide (PI) for the determination of cell cycle distribution of 
cells. Moreover, labeling of additional markers, such as γH2AX (Paper IV), can be performed 
in order of to select cells with DNA damage for analysis or to determine in which cell cycle 
phase DNA damage accumulates. 
When pulsing cells with EdU, it is important to use prewarmed cell medium to minimize 
disturbances in DNA replication caused by temperature changes. When cells are pulsed only 
45 min, EdU-mediated toxicity is neglectable, however, as we used cell synchronization with 
aphidicolin for 24 h to concentrate cells in early-S phase at the time of the drug treatment, cells 
maybe face replication stress that could potentially slow down their replication and cause 
“background” with further drug treatments that disturb replication. When setting up the cell 
gating for flow cytometry cell debris, dead cells (by size) and cell doublets were ruled out from 
the analysis. However, as live-dead staining was not used, it is possible that some dead cells 
remained in the analysis. The gating for cell cycle was based on PI intensity histograms after 
selection of EdU positive cell populations. However, the gate determination is not completely 
accurate by single PI staining and this could cause small errors in the estimation of the cell 
cycle distributions that should not however change the conclusion of the results as gating was 
set as uniformly as possible between different samples. 
3.8 ETHICAL CONSIDERATIONS 
Paper II and Paper IV conducted work with ovarian patient-derived cancer cells which were 
obtained and processed according to the ethical permits 2016/1197-31/1, 2018/118-32 and 
2018/2462-32 approved by the Stockholm Regional Swedish Ethics Review Board. The work 
conducted with this patient material helped us to confirm that CX3CR1 and PFKFB3 inhibition 
had a similar effect in clinically relevant cell models to what we had observed in studies with 




4 RESULTS  
4.1 PAPER I 
Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous 
recombination 
This paper focused on dissecting the role of PFKFB3 in DNA repair upon ionizing radiation, 
revealing that PFKFB3 is involved in the repair of DSBs via regulation of HR repair. 
Immunofluorescence experiments revealed that upon ionizing radiation (IR), PFKFB3 
relocates into nuclear foci (IR-induced foci; IRIF), where it co-localizes with the DNA damage 
marker γH2AX and, to a lesser extent, with 53BP1, RPA and BRCA1. Furthermore, the 
PFKFB3 IRIF was dependent on the ATM kinase activity, γH2AX, MDC1 and the MRN 
complex, which are all integral components of HR repair. Moreover RAD51, RPA32 and 
BRCA1 failed to be recruited into IRIF when PFKFB3 was knocked down by siRNA. To 
provide more evidence on the involvement of PFKFB3 on HR repair, we showed that the HR 
activity of cells is impaired upon PFKFB3 silencing, utilizing a DR-GFP assay235. In 
accordance with decreased HR activity, knockdown of PFKFB3 resulted in delayed G2/M 
progression upon IR, indicating unrepaired DNA damage, ultimately reducing long-term 
survival of irradiated cancer cells in colony-formation assays. Altogether this demonstrated that 
ablation of PFKFB3 disrupts HR repair and sensitizes cancer cells to ionizing radiation.  
We further developed a selective small molecule inhibitor that binds in the substrate pocket of 
PFKFB3. A high throughput screening of 50,000 compounds yielded 105 compounds that 
bound PFKFB3 in nM or low-µM concentrations. From these hits, non-ATP competitive 
compounds were chosen for further development to minimize non-specific activity with other 
kinases. KAN0438241 was identified as a specific PFKFB3 inhibitor that inhibited PFKFB3 
with 20-fold difference in IC50 compared to PFKFB4 and has no effect on the activity of other 
two PFKFB enzymes. Co-crystal structures demonstrated that KAN0438241 binds in the active 
site of PFKFB3, similar as the natural substrate fructose-6-phosphate. To improve cell 
permeability, KAN0438757 was developed, which is an ester of KAN0438241. Upon entering 
the cell, KAN0438757 is converted to its active metabolite KAN0438241, which is responsible 
for the inhibitory effect on PFKFB3. In cellular assays, KAN0438757 reduced the production 
of intracellular F-2,6-P2 and decreased the viability of several cancer cell lines. KAN0438757 
demonstrated intracellular target engagement to PFKFB3 in Cellular Thermal Shift Assay 
(CETSA®)236,237. 
The newly developed PFKFB3 inhibitor KAN0438757 allowed us to investigate if HR repair 
was dependent on the kinase activity of PFKFB3, as the readily available small molecule 
PFKFB3 inhibitor 3PO, failed to mimic the effects on DNA repair that we demonstrated by 
PFKFB3 knockdown. On the contrary to 3PO, inhibition of PFKFB3 by KAN0438757 resulted 
in the blocked recruitment of RPA and RAD51, as well as PFKFB3 itself, into IRIF without 
affecting total protein levels. With KAN0438757, we could replicate the effects of PFKFB3 
knockdown on the HR activity, G2/M phase cell cycle progression and long-term proliferation 
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upon IR. Moreover, KAN0438757 resulted in accumulation of DNA damage post IR as 
demonstrated by the increased γH2AX IRIF at 24h. Taken together, these results indicated that 
the kinase activity of PFKFB3 is required for effective HR repair following IR. 
Next, we discovered that upon IR, PFKFB3 inhibition decreased nucleotide incorporation into 
DNA as measured by EdU pulse in the G2/M phase, and PFKFB3 colocalized with the RNR 
subunit RRM2 in IRIF. We further showed that RRM2 IRIF was dependent on the PFKFB3 
activity, that inhibition of RRM2 resulted in reduced HR activity, and that PFKFB3 and RRM2 
associated physically, as seen in co-immunoprecipitation experiments. Moreover, PFKFB3 
inhibition resulted in a decrease in the total intracellular dNTP pool and stalling of replication 
forks as measured by DNA fiber assays. The fact that we could rescue the replication speed 
and cancer cell proliferation by supplying nucleosides supports the hypothesis that PFKFB3-
mediated dNTP supply is responsible for the effects seen on DNA replication and repair upon 
PFKFB3 inhibition.  
Finally, when compared to hydroxyurea (HU), which limits the dNTP pool by inhibiting RNR 
and induces replication stress, PFKFB3 inhibition did not increase RPA or further checkpoint 
responses. This is in line with our results showing that RPA IRIF are blocked when PFKFB3 
is inhibited. Furthermore, PFKFB3 inhibition blocked HU-induced RPA accumulation and 
checkpoint activation. This demonstrates that replication forks stall upon PFKFB3 inhibition 
due to decrease in local dNTP supply, but do not collapse and checkpoint response is not 
activated. 
In summary, in this paper we discovered an unexpected role of PFKFB3 in DNA repair, 
showing for the first time that PFKFB3 co-localizes directly with DNA repair factors in IRIF. 
The recruitment of PFKFB3 is dependent on MRN complex, ATM, MDC1 and γH2AX 
involved in HR repair. At DSB repair sites PFKFB3 activity regulates the local dNTP pool to 
support repair by the recruitment of RRM2. We conclude that RAD51, BRCA1 and RPA32 
recruitment into damage foci occurs downstream of PFKFB3. The regulatory function of 
PFKFB3 on HR is likely not via its role in glycolysis, as glycolysis occurs in the cytoplasm, 
and we demonstrate that PFKFB3 is readily recruited to DNA damage foci upon IR, co-
localizing with HR repair factors and that loss of PFKFB3 IRIF correlates with impaired HR 
repair. Importantly, we revealed that PFKFB3 inhibition sensitizes cancer cells to ionizing 
radiation at doses not affecting no-transformed cells which present a future possibility of using 
PFKFB3 inhibition as a clinical approach to achieve a greater cytotoxic effect on cancer cells 
without affecting healthy cells. Importantly, we present a new potent, selective, and specific 
PFKFB3 inhibitor, KAN0438757, that can be used as a tool to study the molecular functions 




4.2 PAPER II 
Blocking the fractalkine receptor disrupts replication and ovarian cancer cell 
proliferation 
In this project we evaluated the effects of our small molecule CX3CR1 inhibitor, KAND567, 
in blocking ovarian cancer cell viability and further investigated the regulatory role of CX3CR1 
on ovarian cancer cell replication. We showed that CX3CR1 inhibition by KAND567 reduced 
the viability of ovarian cancer cell lines, in short- and long-term viability assays, without 
affecting non-malignant cells at the same concentrations. The reduced viability was most likely 
due to the dose-dependent induction of DNA damage and apoptosis following treatment with 
KAND567, as assessed by western blot markers and flow cytometry. In addition, KAND567 
was effective in reducing the viability of platinum resistant ovarian cancer tumor cells. We 
further investigated the effects of CX3CR1 inhibition on cell cycle progression and replication, 
showing that cancer cells accumulate in G0/1 and decrease in S and G2/M phases in a dose-
and time-dependent manner upon KAND567, indicating a potential slowdown of G1-S 
transition. Supporting this, serine 780 phosphorylation of the retinoblastoma protein (pRb), 
which drives cell cycle progression from G1 to S, was blocked when CX3CR1 was inhibited. 
However, the decrease in S phase occurred prior to significant G1 accumulation.  
In line with this, replication of ovarian cancer cells, as measured by EdU incorporation in 
immunofluorescence experiments, decreased upon KAND567, indicating impairments in 
replication followed by disturbed G1 to S transition. Furthermore, to assess checkpoint 
response to replication stress upon CX3CR1 inhibition, we showed by immunofluorescence 
that CX3CR1 inhibition leads to early reduction in RPA levels. Moreover, reduction of RPA 
serine 33 phosphorylation, followed by reduced ATR phosphorylation was observed by 
western blot, indicating impaired checkpoint activation via RPA-ATR axis. Interestingly, when 
we inhibited ERK signaling, which is one of the possible downstream effectors of CX3CR1, 
RPA and ATR phosphorylation as well as the phosphorylation of pRb was blocked. However, 
unlike following CX3CR1 inhibition, cells did not enter apoptosis at the time point and 
concentration of ERK inhibitor tested, indicated by the lack of cleaved PARP. 
A combination treatment of KAND567 and carboplatin or IR revealed that in DNA damage 
conditions, CX3CR1 inhibition leads to delayed S to G2/M transition, increased DNA damage 
and increased apoptosis. Consistent with accumulation of cells in S phase, CHK2 was strongly 
activated in co-treated cells indicating intra-S checkpoint activation in damage conditions. 
Notably, we observed that the combination treatment of KAND567 and carboplatin was 
especially effective in platinum resistant ovarian cancer cells although EC50 value for 
KAND567 as a single treatment did not greatly differ between the platinum resistant and 
sensitive cell line pairs. Compared to the platinum sensitive cells, the platinum resistant cells 
displayed a loss in G2/M cell population and induction of DNA damage and apoptosis upon 
KAND567 in combination with carboplatin compared to carboplatin treatment alone.  
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To summarize, in this manuscript we show that CX3CR1 is a driver of ovarian cancer cell 
proliferation and survival, supported by earlier research reports136,141,156,164 and clinical survival 
data141,238. Moreover, by using small molecule inhibitor of CX3CR1, we provide evidence that 
CX3CR1 supports replication of ovarian cancer cells and potentially regulates G1 to S phase 
progression in unperturbed conditions. In contrast, when CX3CR1 inhibition is combined with 
DNA damaging treatments, cells are unable to progress from S phase and display increased 
DNA damage and apoptosis as assessed by western blot markers. Overall, these results indicate 
that CX3CR1 has roles in supporting replication and protecting cancer cells against DNA 
damage and that KAND567 effectively blocks ovarian cancer cell proliferation and sensitizes 
ovarian cancer cells to DNA damaging agents. 
4.3 PAPER III 
Targeting CX3CR1 suppresses the Fanconi Anemia DNA repair pathway and 
synergizes with platinum 
Here we investigated further the combination of CX3CR1 inhibition with platinum drugs in 
cancer cells and the mechanism behind suggested CX3CR1-driven platinum resistance164. By 
performing drug synergy studies, we revealed that KAND567 has a synergistic effect with 
platinum drugs carboplatin and cisplatin on reducing cancer cell survival. High synergy scores 
were achieved especially in platinum resistant cancer cells compared to platinum sensitive cell 
lines and the drug combinations did not yield synergistic scores in non-transformed cell lines. 
To support the inhibitor data, we further demonstrated that siRNA and shRNA mediated 
knockdown of CX3CR1 sensitized the ovarian cancer cell line A2780 to carboplatin and 
cisplatin.  
 As cancer cell resistance upon platinum damage is linked to the FA repair capacity tumors239–
242, we hypothesized that the inhibition of CX3CR1 may interfere with this pathway. As the 
FA pathway regulates the replicative S phase repair, to test our hypothesis, we synchronized 
platinum sensitive and resistant cancer cells to G1/S border by aphidicolin and pulsed them 
with EdU during washout to label replicative cells before exposure to cisplatin and KAND567. 
This allowed us to follow replicating cells upon drug treatment by flow cytometry. When cells 
were treated with cisplatin and KAND567 they arrested strongly in S phase at 6 h post treatment 
which was sustained at the16 h timepoint whereas cisplatin-treated cells progressed throughout 
the cell cycle. Notably, the effect of CX3CR1 inhibition was especially prominent in the 
platinum resistant cells which divided and proceeded to G1 in the presence of platinum, but 
when CX3CR1 was inhibited, a significant percentage of the co-treated cells was still arrested 
in S phase at the 16 h time point. DNA fiber analyses revealed that the fork speed was reduced 
in the co-treated cells, indicating slowdown of replication potentially due to unresolved DNA 
damage. Indeed, when we measured the percentage of DNA-cisplatin adducts after platinum 
treatment by flow cytometry, we noticed that cancer cells were not able to resolve these adducts 
effectively when CX3CR1 was inhibited. Notably, this replication slowdown and accumulation 
of cells in S phase following CX3CR1 inhibition resembles the phenotype of FA cells which, 
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upon ICL induction, accumulate in late S phase243, which encouraged us to investigate 
CX3CR1 further with ICL-inducing agents244. 
In following immunofluorescence studies, we investigated the intracellular localization of 
CX3CR1 in response to treatments that activate the FA pathway244, showing that CX3CR1 
localized to the nucleus in response to cisplatin, mitomycin C (MMC) and hydroxyurea. All 
these drugs activated recruitment of FANCD2 into nuclear foci, consistent with FANCD2 foci 
being a marker for the FA pathway activation245, and we observed that the nuclear intensity of 
CX3CR1 and FANCD2 correlated in response to these drugs. Moreover, when CX3CR1 was 
inhibited or knocked down, FANCD2 nuclear foci formation, in response to cisplatin or MMC, 
was disturbed. Furthermore, by performing chromatin-fractionations of protein lysates, we 
showed that the chromatin-recruitment of both FANCD2 and FANCI, as well as the FA 
pathway downstream factors RAD51 and γH2AX, was blocked upon CX3CR1 inhibition.  
In summary, in this paper we reveal a novel role for CX3CR1 in regulating the FA repair of 
ICL crosslinks, and that CX3CR1 inhibition by KAND567 sensitizes cancer cells to platinum 
treatment while sparing non-transformed cells. These findings could partly explain how high 
CX3CR1 expression can promote platinum resistance in cancer patients, contributing to poor 
survival rates141,150,155. 
4.4 PAPER IV 
PFKFB3 regulates repair of DNA interstrand crosslinks via modulation of the Fanconi 
Anemia repair pathway 
As a starting point of this paper, we hypothesized that PFKFB3 inhibition, due to its newly 
discovered role in DSB repair in Paper I, could synergize with DNA damaging treatments. We 
first revealed that PFKFB3 inhibition by KAN0438757 synergized with platinum in the 
reduction of cancer cell viability and that platinum resistant cells displayed generally higher 
synergy scores. Meanwhile KAN0438757 and platinum combination treatments did not have 
a synergistic effect on non-malignant cells. 
In contrast, the glucose analogue 2-deoxy-D-glucose, which competitively inhibits the glucose-
6-phosphate production246, did not display a cancer-specific effect in reducing viability. 
Furthermore, platinum treatment did not induce significant changes in glycolysis as measured 
by ExtraCellular Acidification Rate (ECAR) and modulating levels of glucose in the cell media 
do not alter sensitivity to carboplatin, indicating that the synergistic effect between PFKFB3 
inhibition and platinum were not due to inhibition of the glycolysis.  
Notably, while PFKFB3 inhibition was equally effective in blocking glycolysis in transformed 
and non-transformed cells, PFKFB3 itself demonstrated a cancer-specific localization to the 
chromatin following cisplatin treatment together with other DNA repair factors as assessed by 
chromatin fractionations. Due to the strong synergy of PFKFB3 inhibition with platinum drugs, 
we wondered if PFKFB3 could be involved in the FA repair of ICLs induced by platinum 
treatment18. Thus, we investigated the dynamics of the nuclear PFKFB3 by 
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immunofluorescence in response to ICL-inducing treatments244, revealing that PFKFB3 
accumulated into nuclear foci and this increased in time dependent manner upon both cisplatin 
and MMC. PFKFB3 foci formation correlated with γH2AX and RPA foci induction following 
these treatments. When we compared platinum resistant and sensitive cells, PFKFB3 
recruitment to the chromatin, along with several FA pathway factors, was enhanced in resistant 
cells constantly cultured with a low cisplatin concentration compared to cisplatin sensitive cells 
receiving a cisplatin pulse. In line with a potential role in the FA pathway, PFKFB3 shRNA 
mediated knockdown rendered cancer cells sensitive to treatments that activate the FA pathway 
(cisplatin, carboplatin, MMC and low dose hydroxyurea)244. 
We further investigated the mechanistic aspects of PFKFB3 recruitment to nuclear foci upon 
the FA pathway activation in immunofluorescence experiments and observed that PFKFB3 
foci formation upon MMC treatment was dependent on ATR kinase activity and FANCM, but 
independent of RPA. On the other hand, recruitment of FANCM, FANCD2, BLM, γH2AX 
and RPA32 into repair foci upon cisplatin and MMC treatments were blocked when PFKFB3 
was inhibited. This data was further supported in chromatin fractionation experiments that 
allowed us to also assess chromatin-binding of additional factors involved in FA repair. These 
experiments revealed that PFKFB3 inhibition blocked the recruitment of FANCI, TopIIIα, 
γH2AX and PCNA. The kinase activity of PFKFB3 was required for its own recruitment into 
repair foci. Moreover, PFKFB3 physically interacted with FANCD2, BLM and γH2AX 
indicating that PFKFB3 has an essential role in the assembly of FA repair factors at the sites of 
ICL damage.  
We next studied the functional consequences of PFKFB3 inhibition in the presence of ICL 
damage. Given the role of the FA pathway in allowing DNA replication to resume following 
ICL damage, we were interested to assess effects of PFKFB3 inhibition in replication upon 
ICL-induction. Accordingly, PFKFB3 inhibition resulted in impaired recovery of replication 
after cisplatin treatment as measured in EdU incorporation assays. Furthermore, DNA fiber 
assays revealed a slowdown of fork speed, fork stalling and a reduction of fork restart after 
MMC and PFKFB3 inhibitor co-treatment, compared to cisplatin or MMC treatments alone. 
Furthermore, γH2AX positive S phase cells were not able to progress throughout the cell cycle 
upon co-treatment whereas cisplatin-treated cells were able to resume their cell cycle 
progression. This suggested that upon PFKFB3 inhibition, replicating cells are not able to 
resolve ICLs which results in an accumulation of DNA damage and S phase arrest. Finally, 
using patient-derived ovarian cancer cells, we confirmed that upon inhibition of PFKFB3, 
cisplatin-induced FANCD2 foci formation was blocked, strengthening our observations of the 
regulatory impact of PFKFB3 in FA repair in a clinically relevant cell model. Altogether these 
findings highlight the importance of PFKFB3 in FA repair and suggests that this function of 





CX3CR1 is a multifunctional regulator of cancer progression127. This thesis work investigated 
the role of CX3CR1 in cancer proliferation and survival, providing evidence that CX3CR1 is 
involved in DNA replication (Paper II) and repair (Paper III) in cancer cells. Based on the 
findings in Paper III, we suggest a nuclear role for CX3CR1 that could function independently 
of the signaling pathways known to be activated downstream of CX3CR1. Besides the results 
presented in Papers II and III, another report164 connecting CX3CR1 to DDR, was published 
during this thesis work. As summarized in Chapter 1.3.2, Xie et al. show that knockdown of 
CX3CR1 by siRNA for 72 h results in inhibition of ATM and DNA-PK activation, followed 
by delay of initial γH2AX induction, increased DNA damage over time and loss of ovarian 
cancer cell viability164. Unlike in our studies with a small molecule inhibitor of CX3CR1, Xie 
and colleagues reported inhibition of CHK2 phosphorylation and overall reduction in RAD50 
levels. However, our assessment of RAD50 total protein levels (unpublished) upon CX3CR1 
inhibition, did not reveal any changes in RAD50 overall levels potentially due to differences 
in cell lines used or the duration of CX3CR1 ablation. In addition, knockdown of CX3CR1 
could have a different effect than targeted inhibition of the receptor due to potential off target 
effects of siRNAs, variable knockdown efficiency and longer time needed for ablation of the 
protein compared to inhibitor due to possible low turnover of the target.  
In Paper III, we show that inhibition and knockdown of CX3CR1 blocks the recruitment of 
FANCD2 following ICL damage. Interestingly, FANCD2 is involved in the repair of DSBs, 
independently from its role in ICL repair247,248. FANCD2 deletion upon DSB induction leads 
to slowdown of replication fork progression, increased S phase arrest, impaired recruitment of 
RAD51 and RPA32, persistent γH2AX foci and increased genome instability248. Thus, the 
DNA damage induction upon CX3CR1 knockdown reported by Xie at al. could result from 
impaired FANCD2 recruitment to DSBs upon IR164. 
Moreover, signaling pathways downstream of CX3CR1 (Figure 8) such as PI3K/Akt, 
MAPK/ERK, EGFR and β-arrestin pathways are connected to the regulation of cell cycle, 
survival, replication, and DDR, and are often activated in cancers249,250. For example, activation 
of Akt signaling in response to cisplatin can be detected in the HGSOC cell line Ovcar-3251 and 
inhibition of PI3K/Akt signaling can re-sensitize ovarian cancer cells to cisplatin252. On the 
other hand, EGFR seems to be an important determinant of radioresistance and EGFR blockers 
have been shown to improve responses to radiation therapy253–255. There are several possible 
mechanisms that could explain how these signaling pathways can drive resistance to DNA 
damaging agents, including involvement in the cell cycle regulation252, crosstalk with DNA 
repair pathways256,257, inhibition of pro-apoptotic proteins160 and modulation of tumor 
microenvironment258, highlighting the various ways survival signaling can modulate the 
response to platinum and radiation treatments. Thus, part of the CX3CR1-induced effects on 
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DDR, could be conferred via CX3CR1-mediated signaling. The following chapters will discuss 
several different mechanisms how CX3CR1 can confer its effects on DDR. 
5.1.1 The nuclear role of CX3CR1 
The traditional view of GPCR signaling includes receptor activation on the cell surface 
followed by G protein and β-arrestin-mediated responses in intracellular signaling pathways 
and eventual termination of the signaling via receptor internalization137. However, GPCRs can 
continue to be active also after internalization and subcellular localization has an important 
functional role for many GPCRs259.  GPCRs are internalized from the membrane to early 
endosomes in a process involving β-arrestins and other proteins and these endosomes can 
subsequently fuse into other phospholipid-containing membranes inside the cell139. So far more 
than 30 GPCRs have been reported to localize to the nucleus and the nucleus contains the 
complete GPCR signaling machinery including G proteins and β-arrestins259. The nucleus 
contains several intranuclear hydrophobic areas such as nuclear membrane invaginations and 
nuclear bodies that can harbor GPCRs in addition to the inner and outer nuclear 
membrane139,259. Interestingly, the CX3CR1 nuclear staining in the confocal microscopy 
studies in Paper III displayed both pan-nuclear but also few concentrated larger foci-like 
CX3CR1 staining areas in part of the cell population which did not clearly co-localize with the 
DNA repair factors assessed (data not shown). In contrast to the pan-nuclear staining which 
increased upon cisplatin and MMC treatments, the larger foci staining was not altered upon 
these treatments. These structures could be attributed to intranuclear hydrophobic areas 
favorable to CX3CR1 docking. Another option is that CX3CR1 localizes to centrosomes which 
have been shown to anchor another GPCR  known as the sphingosine 1-phosphate 5 
receptor260.  
Some GPCRs have been shown to directly associate with the chromatin and be able to regulate 
gene expression. For example, the coagulation factor II receptor-like 1 (F2rl1) translocates 
from the cell membrane to the nucleus and to the chromatin, where it facilitates the recruitment 
of a transcription factor to trigger gene expression leading to neovascularization138. In addition, 
the same F2rl1 receptor that is found at cell surface triggers a signaling cascade that leads to 
expression of genes related to vessel maturation138, highlighting the separate roles of the 
receptor supporting complementary functions of the same physiological process. In a similar 
manner, CX3CR1 could have separate roles in DNA repair and replication via its nuclear role 
and via CX3CR1-mediated signaling pathways.  
Although we could not detect CX3CR1 in distinct DNA repair foci, we discovered that 
CX3CR1 associated to the chromatin and this was increased upon cisplatin and blocked by 
KAND567. A limitation of Paper III is that although CX3CR1 localization to the nucleus and 
chromatin was detected, a direct interaction with DDR factors or DNA damage sites was not 
detected. In follow-up studies, detailed investigation of how CX3CR1 is anchored in the 
nucleus and how it interacts with chromatin and associates with repair factors should be 
assessed by co-immunoprecipitations, by epitope-tagged CX3CR1 and by isolation of lipid-
containing nuclear compartments. Moreover, the use of bioluminescence resonance energy 
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transfer (BRET) assays could make it possible to follow the trafficking dynamics and activity 
of CX3CR1 from the membrane to the nucleus in real-time261. 
In Paper III we also showed that CX3CR1 translocates to, or redistributes in, the nucleus in 
response to DNA damaging treatments that activate the FA pathway. This could potentially be 
achieved by increased CX3CL1 expression and subsequent CX3CR1 activation followed by 
nuclear translocation or redistribution as several chemokine ligands are upregulated in response 
to both radiotherapy and platinum treatments, although radiation-induced inflammatory 
chemokine secretion is better characterized262–265. Another option is that CX3CR1 is 
internalized by ligand-independent mechanisms in response to platinum. Interestingly, EGFR 
has been shown to relocate to the nucleus following treatment with cisplatin and IR and bind 
to DNA-PKcs, possibly in a ligand-independent manner, promoting repair of DNA lesions 
caused by these agents256,266. In a similar manner, CX3CR1 translocation could modulate DNA 
repair kinetics following platinum and radiation treatments. Moreover, ROS, created in 
response to by both platinum and radiation treatments, is an important effector of cell signaling 
and able to activate a variety of receptors and could therefore perhaps activate CX3CR1267. A 
third option is that CX3CR1 exhibits constitutive activity268–270.  
Notably, our preliminary assessment of the effects of CX3CL1 upon platinum treatment 
indicated that excess CX3CL1 does not increase ovarian cancer survival upon platinum (data 
not shown), meaning that the function of CX3CR1 upon DNA damage does not require 
CX3CL1 or that CX3CL1 was already present in adequate quantities and a plateau was 
reached. Future studies should thoroughly investigate if CX3CL1 knockdown influences 
CX3CR1-mediated effects on DDR and if CX3CL1 expression or secretion increases upon 
DNA damage induction. Notably, the fact that KAND567 blocked the CX3CR1-mediated 
events upon DNA damage further expands the utility of this inhibitor in the case that CX3CR1 
activation is found to be ligand-independent. 
5.1.2 The MAPK/ERK pathway 
Paper II provides evidence that ERK1/2 is phosphorylated in the platinum resistant ovarian 
cancer cell line A2780Cis and this phosphorylation is blocked by CX3CR1 inhibition. In 
addition, similar to CX3CR1 inhibition, ERK inhibition blocked the phosphorylation of ATR, 
RPA, and pRb, suggesting that ERK pathway could partly mediate CX3CR1-dependent 
responses in the regulation of DDR. This should be however thoroughly investigated by 
experiments combining CX3CR1 and ERK inhibitors or by cell lines harboring inactive ERK. 
In addition, cleaved PARP was not induced by ERK inhibition alone which indicates that 
blocking ERK signaling is not enough to induce apoptosis and inhibition of other CX3CR1-
mediated events is required for cells to undergo apoptosis. On the other hand, differences in 
the phenotypes resulting from CX3CR1 inhibition and ERK inhibition could also depend on 
the potential different efficacy of the inhibitors used. 
Supporting findings in Papers II and III, inhibition of MAPK/ERK signaling has been shown 
to sensitize cancer cells to DNA damaging agents and ERK can regulate both Akt and ATM 
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activation271–274. For example, inhibition of MEK in MAPK/ERK pathway has been reported 
to sensitize ovarian and pancreatic cancer cells to DNA damaging agents via BRCA2 
downregulation275. Reciprocally ERK can be activated by PIKK kinases and ERK activation 
has been reported for example in response to DSBs and DNA damaging agents such as cisplatin 
and IR276. At the same time that ERK mediates pro-survival signals, it can also promote 
apoptosis, and inhibition of ERK1/2 has been reported to prevent cisplatin-induced apoptosis 
in HeLa cells277, which supports our findings in Paper II. It is suggested that ATM activates 
Akt in response to DSBs, which mediates pro-survival signals, but at the same time activates 
ERK, which can activate apoptotic pathways276. Depending on the extent of DSB damage, 
either survival or apoptosis signals dominate. Due to this dual role of ERK in cancer survival 
and apoptosis inhibition, both ERK and Akt pathway may be required to efficiently stop cancer 
progression278, a strategy that could be possible via CX3CR1 inhibition. 
5.1.3 The PI3K/Akt pathway 
The PI3K/Akt/mTOR pathway is the most frequently altered signaling pathway in ovarian 
cancer and it is associated with poor survival279. Importantly, Akt signaling has been shown to 
promote ovarian cancer proliferation in a CX3CR1-dependent manner161. Akt activation is 
associated with platinum264,280,281 and radioresistance282,283 and its inhibition sensitizes several 
cancer cell lines to these therapies252,284–286. CX3CR1-induced Akt signaling leads to cell 
survival for example by regulating the BCL2 associated agonist of cell death (BAD) in non-
malignant cells121,126,287. However, Akt is also involved in DNA repair and checkpoint 
signaling beyond its role in anti-apoptotic pathways288 and is thus an attractive mediator of 
CX3CR1-induced effects on DDR. Akt phosphorylates DNA-PK to promote NHEJ, and is 
reciprocally activated by all three PIKKs in response to DNA damage facilitating HR repair 
and ICL repair289–291. Inhibition of mTOR, which is a downstream factor of Akt, suppresses 
FANCD2 expression292,293 and mTOR inhibition synergizes with PARP inhibition in BRCA2-
mutated breast cancer cells294 and sensitizes T-cell lymphoblastic leukemia cells to DNA 
damaging agents including cisplatin293. In addition, blocking mTOR leads to potentiation of 
IR-induced S phase arrest and increase in γH2AX295 and mTOR inhibition can selectively 
downregulate factors associated to DDR, cell cycle and survival in platinum-resistant ovarian 
cancer cells 296. Moreover, Akt regulates PCNA ubiquitination in response to UV irradiation, 
and inhibition of Akt can block the recruitment of TLS polymerases impairing replication forks 
and conferring synthetic lethality in HR-deficient cells297. Therefore, reduction in Akt signaling 
could contribute to the DNA repair deficiencies seen upon CX3CR1 inhibition, a hypothesis 
which could be tested in the future for example in rescue experiments by overexpressing a 
constitutively active Akt in the presence of KAND567. 
Interestingly, it has been reported that the PI3K/Akt pathway regulates G1 progression in 
A2780 cells by promoting expression of cyclins and that Akt inhibition leads to inhibition of 
pRb and accumulation of cells in G0/G1298 similar to what was seen upon CX3CR1 inhibition 
in Paper II . Paper II reports that CX3CR1 could drive G1 to S progression in A2780 ovarian 
cancer cells, as CX3CR1-inhibited cells displayed accumulation in G0/G1. On the other hand, 
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when CX3CR1 inhibition was added subsequently after carboplatin treatment, which first 
synchronizes the cell population in S phase, S phase arrest and apoptosis were potentiated 
(Paper II). This phenotype was even clearer in Paper III, showing that simultaneous treatment 
of cisplatin and CX3CR1 inhibition in synchronized replicating cells, leads to an increase in S 
phase arrest. Similarly, Akt inhibition has a protective role in unsynchronized osteosarcoma 
cells by preventing S phase entry when Akt inhibitor is administered at the same time as 
cisplatin284. On the contrary, when cells are treated with cisplatin and Akt inhibitor 
sequentially, Akt inhibition sensitizes cisplatin-treated cells to apoptosis284. This highlights the 
importance of the correct treatment schedule of drugs in combination treatments. As both 
platinum and radiation therapy are most toxic for replicating cells10,299 and CX3CR1 inhibition 
blocks S phase repair, treatment regimens that push the cells into S phase prior addition of 
CX3CR1 inhibitor will maximize the treatment efficacy. 
5.1.4 β-arrestins 
Along with CX3CR1-induced G protein signaling, β-arrestin-regulated pathways are 
interesting candidates for CX3CR1-mediated regulatory effects. Besides their role in 
trafficking and termination of GPCR signaling they work as scaffoldings to elicit multiple 
signaling pathways such as those also activated by G proteins300. Moreover, β-arrestin-1 can 
translocate to the nucleus and regulate gene transcription and histone acetylation301. In addition, 
β-arrestins can transactivate receptor tyrosine kinases and promote another round of G protein 
activation from early endosomes instead of desensitizing the receptor302. The binding of 
CX3CL1 to CX3CR1 induces β-arrestin recruitment174 but the consequences of β-arrestin 
activation in the CX3CL1/CX3CR1 axis have not been well-characterized and they might also 
be tissue-dependent. As summarized in the introduction, it was shown that KAND567 is partial 
agonist on CX3CL1-induced β-arrestin recruitment at low concentrations when both CX3CL1 
and KAND567 are bound to the receptor but nearly completely blocks β-arrestin recruitment 
at the concentrations that displace CX3CL1174. In future studies, it would be interesting to 
elucidate the potential relevance of the partial agonist functions of KAND567 on cellular 
responses as well as the β-arrestin mediated effects of CX3CR1 activation by CX3CL1. 
In summary, CX3CR1 regulates multiple signaling pathways, and future studies should be 
directed towards dissecting which CX3CR1-induced signaling pathways are important in the 
DDR and upon resistance to DNA damaging agents, and to which extend the regulatory effect 
on DDR is attributed to possible uncanonical roles of CX3CR1. Given that CX3CR1 is an 
important driver of malignant processes, its inhibition will convey more targeted effects with 
less toxicity than general kinase inhibitors which interfere with multiple cellular processes as 
they inhibit many kinases unselectively, instead of one activated by a specific GPCR. 
5.1.5 CX3CR1 and replication 
Paper II provides evidence that CX3CR1 promotes DNA replication in ovarian cancer cells 
and CX3CR1 inhibition quickly blocks DNA replication and RPA and ATR phosphorylations. 
Interestingly, it is suggested that Akt/mTOR signaling controls dNTP synthesis by regulating 
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the expression RRM2288,303,304. Moreover, MEK1/2 inhibition on the ERK signaling pathway 
suppresses RRM1 levels via an Akt-dependent feedback loop305 and the combination treatment 
of the mTOR and ERK inhibitors impairs dNTP synthesis by suppression of both RRM1 and 
RRM2 expression resulting in synergistic reduction of renal cell carcinoma cell viability and 
tumor growth in a xenograft model306. Based on these findings, blocking CX3CR1 could 
suppress dNTP synthesis effectively by blocking both Akt/mTOR and ERK and subsequently 
RRM1 and RRM2 expression. Moreover, mTOR inhibition has been shown to prevent PCNA 
loading to the chromatin which leads to replication stress response via ATR and CHK1 
activation307. However, Paper II demonstrated that CX3CR1 inhibition blocks 
phosphorylation of ATR and RPA potentially inhibiting the CHK1-mediated checkpoint 
response, indicating that upon CX3CR1 inhibition the replication stress response is not 
activated.  
The effects of CX3CR1 inhibition on EdU incorporation and replication speed demonstrated 
in Paper II and Paper III, respectively, occur fast within 2 to 4 hours, which makes it worth 
to consider that the effects on replication could result from the blocked FANCD2 recruitment 
to the chromatin upon CX3CR1 inhibition (Paper III). FANCD2 is required in normal 
replication to maintain sufficient firing of replication origins308, it facilitates replication of 
common fragile sites309 and promotes re-start of stalled replication forks also in the absence of 
ICL induction310–312, thus by blocking FANCD2 recruitment to replication forks, CX3CR1 
inhibition could quickly reduce overall replication. Moreover, during high endogenous 
replication stress of cancer cells, the importance of FANCD is further highlighted as it stabilizes 
replication forks and its depletion results in spontaneous endogenous damage313. Taken 
together, block of FANCD2 could be responsible of the impairment of replication and in 
addition increase replication stress above tolerable threshold to kill cancer cells upon CX3CR1 
inhibition without additional DNA damaging agents.  
5.2 PFKFB3 
5.2.1 KAN0438757 as a selective PFKFB3 inhibitor  
Several inhibitors of PFKFB3 have been developed and used in studies aiming to target 
PFKFB3, but surprisingly, most of them do not target the kinase function of PFKFB3 or are 
not specific216,217,223,224, which has made it difficult to interpret the results of these studies. For 
example, Paper I demonstrated that 3PO could not mimic the effects seen upon PFKFB3 
knockdown and later it has been shown to inhibit glycolysis without binding to PFKFB3217. 
Moreover, the 3PO analogue, PFK-158 was also shown to have no effect on the enzymatic 
activity of PFKFB3 although it reduces the glycolytic flux and decreases F2,6BP223. In Paper 
I, a highly selective PFKFB3 inhibitor, KAN0438757, was developed which impaired the 
kinase activity of PFKFB3 and demonstrated intracellular target-engagement which was 
maintained at least 72 h, indicating a long-lasting inhibitory effect. Furthermore, KAN0438757 
reduced cancer cell viability in concentrations that rendered non-transformed cells unaffected 
which encourages its potential as a drug candidate. In addition, the development of 
KAN0438757 facilitates the research on the function of PFKFB3 as a cancer target, compared 
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to the investigation of the general function of glycolysis on cancer that was possible with the 
“older” compounds. 
KAN0438757 is used further in Paper IV where it synergized effectively with platinum drugs 
showing a good therapeutic window compared to non-malignant cells. Notably, KAN0438757 
is well tolerated in mice without systemic toxic effects which encourages its use in future in 
vivo studies207. However, most of the discoveries in Paper I and IV were done in a panel of 
different cancer cell models including pancreatic and ovarian cancer cell lines, patient-derived 
cells, an osteosarcoma cell line and the BJ transformation series. Therefore, it would be 
interesting to evaluate the sensitizing effect of KAN0438757 to platinum and radiation both in 
vivo and in a larger panel of patient derived cells for future selection of responding patient 
subgroups and to evaluate the utility of KAN0438757 as a clinical candidate. 
5.2.2 Nuclear and cytoplasmic roles of PFKFB3 in DNA repair and 
replication 
Paper I and Paper IV provide evidence on the importance of PFKFB3 in the regulation of 
DNA repair and replication, showing that inhibition PFKFB3 interferes with HR and FA repair. 
During these studies, the nuclear role of PFKFB3 was further connected to DNA repair in 
additional pathways; PFKFB3 was reported to locate to the nucleus in liver cancer where it by 
interacting with Akt was suggested to upregulate the DNA excision protein ERCC1210. In this 
report, inhibition of PFKFB3 resulted in increased DNA damage and reduction of tumor 
growth in vivo210. However, the in vivo study was performed with PFK15 compound220, which 
is another 3PO derivative that was synthesized in the development series prior to PFK158, and 
thus the inhibitory effect on tumor growth is likely conveyed via inhibition of glycolysis and 
not by targeted PFKFB3 inhibition. Paper I and IV demonstrated for the first time that 
PFKFB3 associates directly to the chromatin at the DNA damage sites and co-localizes with 
repair factors, providing evidence that PFKFB3, besides activating signaling cascades that lead 
to regulation of DNA repair factors, can directly interact with them, and modulate their 
recruitment to damage sites. 
In line with Paper I and IV revealing an important role for PFKFB3 in functional FA and HR 
repair, inhibition of PFKFB3 radiosensitized cancer cells and displayed a cancer-specific 
synergy with platinum. Our findings regarding a key role for PFKFB3 in maintaining genome 
integrity upon DNA damaging treatments has been supported by findings of other research 
groups during the course of this thesis work. PFKFB3 has been demonstrated to be activated 
in response to chemotherapy and to promote resistance to chemo- and radiotherapy in cancer 
cells, but whether this was due to its nuclear or cytoplasmic role, was unclear in these 
studies203,314,315. Cisplatin was shown to increase glycolysis in HeLa and about 12 % of the 
PFKFB3 pool sequestered to the cytoplasm by acetylation in response to cisplatin treatment314. 
These results are in contrast with our findings in Paper IV showing that platinum treatments 
do not induce a preference for glycolysis and that the survival of cancer cells upon platinum 
treatments was not affected upon altering glucose levels in the cell media which could be due 
to differences in cell models used in the studies. In support, Yalcin et al. previously discovered 
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that PFKFB3 can increase cell proliferation without modulating intracellular glucose 
metabolism182. In addition, in Paper IV PFKFB3 was recruited to the chromatin in response 
to ICL-inducting treatment in cancer cells. Discrepancies between the interpretations of the 
findings in these two studies could, apart from different cell types used, be explained by the 
fact that only 12 % of PFKFB3 was acetylated in HeLa cells in response to cisplatin and that 
PFKFB3 nuclear foci upon these conditions was not assessed, meaning that although part of 
the PFKFB3 pool was retained from the nucleus, a major part of PFKFB3 could still have a 
functional role at the chromatin.  
Moreover, chemoresistant ovarian cancer cell lines were demonstrated to have a higher basal 
rate of glycolysis by another research group, but glycolysis rate in response to treatment with 
chemotherapeutics was not assessed203. Furthermore, another report showed that PFKFB3 
knockdown sensitized endometrial cancer cells to platinum drugs and increased DNA damage 
potentially via inhibition of HR caused by suppression of total RAD51 protein levels and 
Akt/mTOR pathway315. In comparison, Paper I reported that PFKFB3 inhibition impaired 
RAD51 foci formation upon IR but not total RAD51 levels indicating that PFKFB3 disables 
RAD51 recruitment to DNA damage sites without interfering with the total levels of RAD51. 
Conversely, the report by Xiao and colleagues did not assess nuclear PFKFB3 directly or the 
foci formation of RAD51315. Taken together, the reduction of RAD51 in endometrial cancer 
cells and the reduction of RAD51 foci demonstrated in Paper I upon PFKFB3 ablation are 
most likely conveyed via separate PFKFB3-dependent mechanisms. Importantly, in Paper IV 
we reveal that PFKFB3 inhibition sensitizes cancer cells to platinum drugs by blocking the 
initiation step of ICL repair via inhibition of the recruitment of FANCM, FANCD2 and BLM 
to the damage sites, placing PFKFB3 upstream of the HR repair step. Therefore, the 
sensitization to cisplatin reported by Xiao et al., could be the result of the novel role of PFKFB3 
in ICL repair, instead of the earlier suggested HR repair. 
Paper I shows that PFKFB3 recruits RRM2 to the DNA damage sites thus promoting dNTP 
synthesis and HR repair upon IR. Inhibition of PFKFB3 impaired the recruitment of RAD51, 
RPA32 and BRCA1 to the damage sites. Interestingly, PFKFB3 colocalized with DSB repair 
proteins, indicating that PFKFB3 acts as a scaffold for RRM2 to directly provide dNTPs to the 
DNA damage sites where the need for dNTPs is high, especially in HR repair which requires 
extensive DNA synthesis86,87. Notably, depletion of another glycolytic enzyme, 
Phosphoglycerate mutase 1 (PGAM), depletes dNTP pools via its enzymatic activity which 
leads to increased degradation of CtIP, impaired HR and synergy with PARP inhibitors 
regardless of functional BRCA1/2316. 
As it was suggested that Tip60 recruits the RRM1 subunit of RNR complex to the DNA 
damage317, we investigated whether PFKFB3 and Tip60 could coordinate the recruitment of 
RRM2 and RRM1 in response to DNA damage and whether they are dependent on each other, 
but could not successfully identify any evidence for this (data not shown). In future studies, it 
would be interesting to discern, if the regulatory effects of PFKFB3 via dNTP supply extend 
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to other forms of DNA repair than HR, although the requirement of dNTPs is highest in HR 
compared to other DNA repair pathways87.   
In contrast to HR repair upon IR (Paper I), we found that γH2AX foci-formation upon ICL 
repair was PFKFB3-dependent (Paper IV), which supports the hypothesis that PFKFB3 acts 
at a very upstream step of ICL repair. However, γH2AX is also required for FANCD2 
localization to the damage sites318, which indicates that PFKFB3 regulates both these factors 
by promoting an upstream factor, such as recruitment of BLM. Interestingly, in BLM-deficient 
cells γH2AX activation is delayed following replication stress induction, and T99-
phosphorylated BLM co-localizes with γH2AX upon replication damage, indicating that BLM 
could facilitate H2AX phosphorylation319.  BLM is essential in promoting the re-start of stalled 
replication forks upon ICL damage311, for recruitment of FANCM to stalled forks94 and in 
DNA end-resection in HR repair320, which could extend the regulatory roles of PFKFB3 in 
multiple steps of ICL and HR repair depending on whether PFKFB3-controlled BLM 
regulation is direct or a FA repair-specific event. Future studies should determine which is the 
critical direct regulatory step of PFKFB3 in the initiation of ICL repair and how much of the 
effects on ICL repair seen in Paper IV can be attributed to the regulatory function of PFKFB3 
on dNTP supply and vice versa. Finally, due to the central role of RAD51 in HR, several 
inhibitors and monoclonal antibodies have been developed aiming to block the interaction of 
RAD51 with chromatin, yet unsuccessfully, partly due to lack of specificity against RAD51321. 
As PFKFB3 inhibition blocks RAD51 foci formation, targeting PFKFB3 could serve as an 
effective strategy for RAD51 inhibition. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
This thesis work reveals novel roles for CX3CR1 and PFKFB3 in the DDR, promoting cancer 
cell viability and treatment resistance. Paper II shows that CX3CR1 supports cancer cell 
viability by enhancing DNA replication and Paper III reveals that CX3CR1 promotes ICL 
repair. Furthermore, Paper I shows that PFKFB3 has a role in HR repair and in directed supply 
of nucleotides. In Paper IV we discovered that PFKFB3 has a crucial role in the initiation of 
ICL repair. Importantly, inhibition of these targets by KAND567 and KAN0438757 sensitizes 
cancer cells to DNA damaging treatments while sparing non-malignant cells. The best-known 
mechanism of resistance to platinum, and also to PARP inhibitors, is the somatic reversion of 
the original mutation (such as BRCA1/2) that rendered tumors deficient in FA or HR repair and 
resulted in an initial good response to platinum322,323. Furthermore, the FA pathway activity is 
enhanced in many platinum resistant tumors239–242. Thus, inhibition of HR and FA repair by 
KAND567 and KAN0438757 has implications in clinically relevant scenarios. Moreover, both 
KAND567 and KAN0438757 are well tolerated in vivo which encourages their future clinical 
development for cancer indications175,207. In addition, combining inhibition of both targets 
could result in a synergistic effect by blocking DNA repair and replication in a more complete 
manner, a strategy worth exploring further. 
CX3CR1 and PFKFB3 have multiple converging functions. Paper I and III show that 
PFKFB3 and CX3CR1 can regulate unperturbed DNA replication and Paper III and IV 
demonstrate that both targets are involved in ICL repair. Moreover, it was shown that CX3CR1 
can also regulate HR repair164.Inhibition of both targets results in cancer-specific synergies 
with platinum drugs (Paper III and IV). An interesting next step would thus be to assess 
whether inhibition of either target could regulate the recruitment of the other in DNA repair 
and replication, and whether CX3CR1 and PFKFB3 have redundant or complementary roles 
in the DDR. Assessment of a possible correlation between CX3CR1 and PFKFB3 expression 
profiles across cancers could serve as an informative starting point.  
Our results showing DNA repair deficiencies upon CX3CR1 and PFKFB3 inhibition open the 
possibility for additional combination therapies targeting DNA repair. For example, PARP 
inhibitors have the potential to be effective in combination with CX3CR1 and PFKFB3 
inhibition for several reasons. First, as both CX3CR1 and PFKFB3 are involved  in HR, by 
inhibiting these targets PARP-inhibited cells would not be able to repair either SSB or DSB 
damage efficiently, which could result in similar synthetic lethality as seen in HR-deficient 
cancers6. Secondly, both CX3CR1 and PFKFB3 inhibition could synergize with PARP 
inhibitors due to PARP trapping, since the FA pathway is involved in removing trapped PARP 
from the chromatin32. Therefore, by inhibiting the FA pathway, PARP-DNA complexes might 
not be repaired efficiently, leading to increased replication stress. Moreover, rewiring of the 
DNA repair pathway can lead to cancer cell resistance to PARP inhibitors. For example, loss 
of 53BP1 and its effector Shieldin can partially restore HR and promote resistance to PARP 
inhibitors in BRCA1-deficient models74,324,325, thus disabling HR repair by PFKFB3 and 
CX3CR1 inhibition could circumvent development of PARP resistance by HR restoration. 
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Furthermore, combining CHK1 or CHK2 inhibitors with CX3CR1 or PFKFB3 inhibition could 
lead to synergistic responses due to checkpoint override, despite uncompleted repair when 
combined with another DNA damaging agents. For example, CHK1 inhibition combined with 
suppression of FA pathway sensitizes lung cancer cells to gemcitabine326. Moreover, Paper II 
showed that CX3CR1 inhibition by KAND567 alone resulted in phosphorylation of CHK2, 
showing that inhibition of CHK2 might increase replication stress and DNA damage upon 
CX3CR1 inhibition. Finally, further drug synergy studies with a larger panel of DDR inhibitors 
and chemotherapeutic agents combined with KAND567 and KAN0438757 could help to map 
the type of DNA lesions that CX3CR1 and PFKFB3 assist repairing as well as show the extent 
of DDR processes they are involved in. 
Further studies regarding the functions of CX3CR1 and PFKFB3 in the DDR are needed to 
pinpoint their value as clinical candidates in cancer therapy, to find rational treatment 
combinations and to understand which molecular cancer signatures could be best targeted with 
CX3CR1 and PFKFB3 inhibition. As we move towards personalized medicine, future studies 
should elucidate which molecular backgrounds of cancer cells make them dependent on 
CX3CR1 and PFKFB3 for survival during DNA damage and replication stress, and which 
mechanisms are able to rescue cancer cell viability upon inhibition of these targets. In addition, 
cancers lacking these proteins might possess targetable DNA repair vulnerabilities. Finally, 
assessment of the potential of CX3CR1 and PFKFB3 as cancer biomarkers could improve 
patient stratification and the chance of successful clinical trials, leading to improved treatment 
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